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General introduction
Approximately one in eight women in the Netherlands will develop breast 
cancer during her lifetime.
1
 Fortunately, due to the increased awareness among 
women about the early signs of breast cancer, implementation of population 
based screening programs and advancements in treatment options, a large 
proportion of these women will survive the initial treatment phase. The fact that 
more women are successfully being treated for breast cancer has caused a 
shift of attention towards the period after active cancer treatment, also known 
as the period of survivorship. 
2
 Survivorship refers to the period following active 
cancer therapy, the period in which the late effects of treatment occur. 
3
 In 
saying this, the management of the late effects of breast cancer treatment is 
imperative for maintaining an acceptable long-term quality of life. Of the late 
effects of breast cancer treatment, lymphedema is one of the most 
underestimated and debilitating morbidities. 
4-6
 Between 6% and 43% of breast 
cancer survivors develop breast cancer related lymphedema (BCRL).
7, 8
 The 
large variability in the reported figures of BCRL is explained by differences in 
the definitions used and by differences in treatment and risk factors between 
populations. Adjuvant treatment for breast cancer, such as axillary surgery, 
radiation and chemotherapy can cause damage to the lymphatic system of the 
upper-limb resulting in lymph fluid stasis and an increased limb volume. 
9, 10
 
This limb swelling may present with symptoms of heaviness, tightness and pain 
sensations. Furthermore, loss of normal upper-limb function and range of 
motion can be experienced. The negative psychological effects brought on by 
the impairments of activities of daily life and reduced limb aesthetics constitute 
an additional burden.
5, 11,12 
 An overview of the important aspects of BCRL such 
as the etiology, pathophysiology, diagnostic techniques and treatment options 
will be given in this chapter, as well as the aims of this thesis, following from this 
overview. The onset of BCRL can occur any time after primary cancer 
treatment, but in most cases develops in the first four years after treatment.
13
 
The following risk factors are associated with the development of BCRL: the 
extent of breast/axillary surgery, adjuvant radiation, adjuvant chemotherapy, the 
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number of positive lymph nodes, treatment on the side of the dominant limb, 
older age and obesity. 
14-16 
 
 
Pathophysiology 
 
Basic knowledge on the working mechanism of the lymphatic system is 
necessary in order to understand the pathophysiology of BCRL. The lymphatics 
of the upper extremity are divided into superficial and deep vessels, which form 
two communicating systems. The superficial (epifascial) vessels transport 
lymph fluid from the skin, subcutis and structures therein. Whereas the deep 
system (subfascial) transports lymph fluid from muscles, fascia, nerves, joints, 
ligaments and bones.
17
 Moreover, the axillary lymph nodes receive lymph fluid 
from the upper extremity, supra-umbilical anterolateral body wall and part of the 
breast.
17
  Lymph fluid transport is determined by interstitial pressure in extra 
cellular spaces, which in turn is influenced by three important factors: by the 
contraction of subjacent skeletal muscles, arterial pulsation near lymphatic 
vessels and by contraction of smooth muscle cells in the lymphatic wall 
stimulated by the sympathetic nervous system.
18
 Lymph vessels, like other 
vascular structures, are trilaminar and consist of 
19
:  
- An internal membrane, containing endothelial cells; 
- A medial membrane, containing varying proportions of smooth muscle 
cells; 
- An outer membrane, extra cellular matrix containing fine bundles of 
collagen and elastin fibers. 
 
The limb swelling that is seen in BCRL is the result of a combination of an 
accumulation of protein rich fluid in the interstitial tissues, tissue fibrosis, fat 
deposition and thickening of the skin.
17
 Its chronic and progressive nature 
makes BCRL an intricate disease. The International Society of Lymphology 
(ISL) has developed a widely used and accepted staging system based on 
clinical assessment. The ISL staging system consists of three stages each 
representing a phase in disease progression (Table 1). 
20
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Table 1: International Society of Lymphology staging system 
0 Subclinical stage; swelling not evident despite impaired lymph transport 
I Early accumulation of fluid which subsides with limb elevation, pitting may 
occur 
II a Limb elevation rarely reduces tissue swelling, pitting is manifest 
II b Excess fat and fibrosis supervene, the limb may or may not pit 
III Lymphostatic elephantiasis 
 
Damage to the local (breast/axilla) lymphatic system causes obstruction of 
normal lymph flow, which leads to lymph stasis and an increase of pressure in 
the collecting lymphatics.
21
 The exact histopathological changes that occur as a 
result of the lymphatic outflow impairment are yet to be fully elucidated. 
However, the few studies available focusing on the ultra-structural aspects of 
edema, have given us some insight.
18, 21-26
 As a reaction to tissue injury an 
inflammatory process is triggered, activating lymphocytes and leukocytes that 
release cytokines. Degeneration of media smooth muscle cells and the 
proliferation of collagen fibers further impair lymph fluid drainage.
21, 24-26
 The 
excessive deposition of extracellular matrix, especially collagens, is the 
complex tissue response that is called fibrosis.
22
 In case of inadequate disease 
management, lymphedema progresses: arm-swelling transforming from a 
predominantly fluid encompassing entity to fibrosis and fat.
24
 BCRL in its late 
chronic phase is irreversible and accompanied by more symptoms and physical 
impairments. The time-line in which disease progression takes place, remains 
unknown.  
 
Measurement techniques 
Part of the wide range in the reported incidence and prevalence rates of 
lymphedema is due to the lack of a uniform measurement protocol and criteria 
for diagnosis.
27-44
 Moreover, the different measurement techniques have 
considerable intra- and inter-rater variability. The affected limb is usually 
General introduction 
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compared to the non-affected side, irrespective of the type of measurement 
technique. Measurement techniques most commonly used are the following:  
Water displacement technique
31
: this is considered the current “golden 
standard”, in which limb volume is assessed using an inverse water 
displacement volumeter. The criteria for the diagnosis of BCRL using this 
technique is a difference in limb volume of 200ml or more between the affected 
and non-affected contralateral limb.  
Circumferential limb measurement
27, 28
: here a tape measure is used to 
assess limb girth at predetermined intervals along the limb. A difference 
between the affected and non-affected contralateral arm of 2cm or more at any 
measured point is considered clinically significant limb swelling.  
Optoelectronic perometry
35-37
: here infrared laser technology is used to 
assess limb volume. The contralateral unaffected limb as a comparison is also 
used for lymphedema diagnosis, a volume difference of 10% or 200ml or more. 
However, the above-mentioned techniques used for assessing limb volume 
represent an indirect measurement of BCRL. These techniques do not take 
tissue composition into account, and thus make no distinction between extra- 
and intracellular fluid when measuring limb volume. Furthermore, volume 
assessment does not give an indication of the severity of the BCRL. 
Bioimpedance spectroscopy (BIS) is an alternative method for assessing 
BCRL that uses skin electrodes to pass a small alternating current through a 
limb and measures the impedance to the flow of this current.
36, 38, 39
 The fluids in 
the body conduct electrical current and as fluid volume increases, impedance to 
current flow decreases. BIS therefore gives a measure that correlates with the 
amount of extracellular fluid.  
Disease specific questionnaires can be used to diagnose BCRL and also 
measure the consequences of the symptoms on the quality of life.
27, 43, 44
  
Patient reported signs and symptoms are often the first indication of clinically 
relevant lymphedema.
27
 The symptoms women with BCRL may present with 
include: tingling, pain heaviness, reports of poor clothing fit, or even as minimal 
as the limb “feels different”. 
27,43  
Examples of disease specific questionnaires 
are the Wesley Clinic Lymphedema Scale (WCLS)
45
, the Freiburg Life Quality 
Assessment (FLQA-1)
46
, the Upper Limb Lymphedema 27 (ULL-27)
47
and the 
Lymphedema, Functioning, Disability and Health (Lymph-ICF)
48
.  
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Treatment 
The current standard of treatment for BCRL is a combination of different 
methods of conservative therapy, also known as complex decongestive therapy 
(CDT)
49
 CDT incorporates two stages of treatment. The first treatment phase 
entails: skincare, exercises aimed at improvement of mobility/range of motion in 
the shoulder, elbow or wrist joints, compression therapy through multi-layered 
bandaging and manual lymphatic drainage (MLD). Moreover, MLD is the 
manual stretching and pressure application to the skin in slow, rhythmic and 
circular motions to stimulate the activity in the lymphatic vessels to increase 
lymphatic fluid drainage. In the second treatment phase, CDT is aimed at 
maintenance of the achieved limb volume/ circumference reduction through 
compression therapy in the form of therapeutic elastic stockings for the arm. 
Skincare, mobility exercises and MLD is continued in this phase if needed. In 
addition to CDT, other methods can be applied, including intermittent pneumatic 
compression (IPC) and kinesio taping. 
 
IPC is a device with pneumatic cuffs connected to a pump that mimic the 
naturally occurring muscle pump effect of muscles contracting around 
peripheral lymphatics.
49 
 
 
Kinesio taping is a method used mostly by athletes, is used in some instances 
for BCRL with the hypothesis that it can help improve lymphatics and reroute 
lymph in superficial lymphatic vessels.
50, 51
 
 
These two additional therapeutic methods are applied dependent on the 
preference of the lymph therapist, as the literature contains no evidence on the 
most effective combination of treatments. 
 
Conservative therapy is initially aimed at alleviating symptoms without curative 
intent, which for most patients means lifelong treatment. Dutch breast cancer 
treatment guidelines suggest a three-month treatment period with compression 
stockings in case of a 5-10% limb volume increase.
45
 Adding compression 
therapy to complete decongestive therapy could induce significant limb volume 
reduction. When maximum limb volume reduction is achieved compression 
stockings should be worn for the rest of the patient’s life. A systematic review 
evaluating the effects of conservative and dietary interventions for BCRL 
demonstrated compression garments or compression bandaging to reduce limb 
lymphedema volume, with a reported percentage reduction ranging from 17% 
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to 60 %.
48
 Furthermore, a statistically significant beneficial effect was found for 
the addition of MLD to compression therapy for reducing upper extremity 
lymphedema volume.  
 
Surgical intervention to treat BCRL in the form of lymphatic microsurgery is 
mentioned in Dutch lymphedema guidelines, although the exact role of such 
interventions is not made clear as the current evidence base for the 
effectiveness of Lymphatic microsurgery as treatment for BCRL is 
ambiguous.
53-61
 More importantly, no prospective randomized trials have been 
published as of yet.  
 
 
Aim and outline of this thesis 
The main purpose of the studies described in this thesis is to gain more insight 
on BCRL in order to substantiate the need for improvement of its management 
amongst breast cancer survivors.  
Firstly, in Chapter 2 we investigated the prevalence of BCRL in a group of 
breast cancer survivors 5 years after initial treatment, using three different 
measuring methods. Knowledge on how lack of uniform criteria for the 
measurement of BCRL may affect its prevalence is essential for interpreting 
current literature on BCRL.  
 
Next, in Chapter 3 the quality of life of women with BCRL was assessed in the 
same cohort of breast cancer survivors. All these women were treated in the 
sentinel lymph node biopsy era.  
 
In Chapter 4 the biomechanical properties of the skin of the arm of women with 
BCRL were compared with the properties of the skin of their healthy arm. This 
was done to determine how BCRL affects the elasticity, visco-elasticity and 
level of hydration of the skin. 
 
The role of breast reconstruction as a possible risk factor or protective factor for 
the development of BCRL in women after mastectomy is explored in Chapter 5.  
 
In Chapter 6 we assessed if the improvement in quality of life, which is usually 
seen in breast cancer survivors after reconstructive breast surgery, was 
influenced by the presence of BCRL. 
Chapter 1 
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Chapter 7 gives an overview of studies on the effectiveness of different 
microsurgical treatment options for BCRL.  
 
In Chapter 8 an overview of the current changes taking place in axillary staging 
and treatment of breast cancer patients is given with the aim to identify patients 
with a high risk of developing morbidity in the arm and/or shoulder.  
 
Chapter 9 describes a strategy to improve early detection and the treatment of 
BCRL.  
 
Chapter 10 concludes this thesis with a general discussion, including 
conclusions and approvals for clinical practice and future research. 
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Abstract 
Aim: The lack of consistency in the definition of breast cancer related 
lymphedema (BCRL) and of uniform measurement criteria contributes to the 
wide prevalence range found in current literature. This report aims to describe 
the long-term prevalence of BCRL and secondly, to compare the long-term 
prevalence of BCRL when assessed by two objective measures and one 
subjective measure.  
Methods: The upper limbs of 145 post-surgical breast cancer patients were 
evaluated for the presence of lymphedema using the water displacement 
method. Two circumference methods and patient perceived swelling were 
applied secondarily for comparison. Limb measurements were performed once, 
more than five years after surgery. 
Results: The long-term prevalence of BCRL using water displacement was 8%. 
Prevalence varied when the sum of arm circumference (SOAC), the arm 
circumference and the self-report methods were used: 16, 31 and 17% [P 
<0.001], respectively. Of the women identified with BCRL using the water 
displacement technique, 82% were detected with the SOAC method, 82% with 
the arm circumference method and 91% by self-report. Using water 
displacement as the gold standard the methods with the highest specificities 
were the SOAC (90%) and self-report method (89%), arm circumference 
resulted in a low specificity of 73%.  
Conclusion: The prevalence of BCRL more than five years after surgical 
treatment differs depending on the measuring method used. Our data 
underlines the necessity for consensus on the diagnostic criteria for BCRL.  
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Introduction 
 
Early breast cancer detection and concomitant advancements in treatment 
options have not only resulted in an increase in breast cancer survival rates, but 
also in that of disease related morbidities with upper limb lymphedema being 
one of the most debilitating. Swelling of the oedematous limb is brought on by 
obstruction of normal lymph flow, with known treatment risk factors which cause 
damage to the lymph vessels being axillary dissection, mastectomy and 
adjuvant radiation therapy.
1 – 7
   
Breast cancer related lymphedema (BCRL) could present with pain, loss of 
sensibility, strength and mobility of the affected limb, reducing activity and 
causing physical and psychological impairments. 
8-12
 Lack of consistency in the 
definition of BCRL and a lack of uniform measurement criteria have contributed 
to the wide prevalence range found in current literature.
1-4
 This is illustrated in a 
review on the late morbidity after treatment of breast cancer, in which the 
prevalence was reported to range between 6 and 43%
5   
Moreover, few studies 
have described the long-term prevalence of BCRL
13 – 16
 and none, to our 
knowledge, have done so with the use of different measuring methods within 
the same patient group.  
Therefore, the current study was conducted primarily with the aim of assessing 
the long-term prevalence of BCRL in women more than five years after breast 
cancer treatment. We also sought to assess the source of variation in BCRL 
prevalence by comparing prevalence outcomes of four different measuring 
methods (water displacement method, two arm circumference methods and 
self-reported limb swelling. 
 
Methods 
Patients 
 
A database of patients treated at the Maastricht University Medical Centre 
(MUMC+) between January 2001 and December 2003 was queried to identify 
women operated for breast cancer five or more years prior to search (n=386). 
Exclusion criteria were death (n=96), migration (n=8) and loco-regional 
recurrence (n=34). 248 eligible women were asked to take part in our study. 93 
patients withheld written consent and ten patients ultimately did not take part 
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due to personal circumstances or illness, resulting in a study population of 145 
women. The hospital’s medical ethics committee approved the study and the 
consent form.  
  
Lymphedema Measurements 
 
Four methods were used to assess the long-term prevalence of BCRL: the 
water displacement method, two arm circumference methods and the self-
report method. The water displacement method was regarded as the gold 
standard. In order to evaluate the type of measurement as a probable source of 
variance, we compared the prevalence of the two circumference methods and 
the self-report method with the gold standard. All limb measurements were 
performed at one moment in time, five or more years after breast cancer 
surgery. For each method the breast cancer treated side was compared to the 
untreated side. One researcher (JS) performed all limb measurements.  
 
1. Water displacement method 
 
For the assessment of upper-limb volume a home built volumeter was used 
according to J. Lette.
17
 This method carries a high reproducibility.
18
 A line was 
drawn at 80% of the arm length, measured from the tip of the third digit to the 
tip of the acromion. Subjects were instructed to lower the arm straight and 
slowly into the volumeter and to stop and keep it still when the 80%-line 
reached the water surface. Both upper-limbs were measured twice. The 
overflowing water was collected in a bucket and weighed on a calibrated scale. 
(PR balance, Mettler-Toledo, Switzerland). The conversion value of 1kg = 1000 
mL was applied. Lymphedema was defined as a limb volume difference greater 
than 200 mL between the treated and untreated side. 
 
2. Circumference method 
 
The arm circumference was measured at ten sites on both limbs using a tape 
measure. The locations measured were: mid-metacarpal, the wrist and at 20, 
15, 10 and 5 cm below and above the elbow fold. The sum of these 
circumferences was calculated per limb. Lymphedema was defined as a 
difference of the sum of arm circumferences (SOAC) of more than 5 cm 
between the treated and untreated side or as a difference of arm circumference 
of more than 2 cm between the treated and untreated side at any of the 10 
measured locations on the limb.
19
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3. Self-reported lymphedema 
 
Patients were asked to indicate the presence of (refractory) swelling during a 
standardized interview by answering the following question with a “yes” or “no”: 
Have you experienced swelling of the upper-limb on the breast cancer treated 
side in the past year? Self-assessment was described as negative or positive 
for BCRL. 
 
Statistical Analysis 
 
Patient and clinical characteristics were described using descriptive statistics. 
Continuous variables were evaluated for normal distribution and expressed by 
providing the median and range. χ
2
 was used to test the relationship between 
categorical variables. A P-value <0.05 was considered statistically significant. 
The sensitivity and specificity were measured for the SOAC, the circumference 
and the self-report methods, using the water displacement method as a 
reference. All data-analysis was conducted using SPSS for Windows 17.0 
(SPSS Inc. Chicago, Illinois). 
 
 
Results 
 
Patient Characteristics 
 
The 145 women included in this study were evaluated for BCRL after a median 
period [range] of 6.2 years since time of surgery [5.0 – 7.8]. At time of surgery, 
subjects’ age ranged from 33-86 years with a median of 55.0 years. The 
median [range] body mass index (BMI), calculated using the patients weight 
and height at time of surgery, was 25.1 [17.1- 48.9]; a total of 28 patients were 
considered obese (BMI ≥ 30) at that time. The majority (n=123) of the women 
underwent breast-conserving surgery; 22 women underwent ablative breast 
surgery. Of all patients, 69 had an axillary lymph node dissection (ALND) and 
76 had a sentinel lymph node biopsy (SLNB). Radiation treatment either to the 
breast or chest wall and supraclavicular was given to 125 women.  
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Lymphedema measurements 
 
Using the gold standard, 11/145 women met the criteria of the water 
displacement method for the diagnosis of lymphedema. When patients were 
evaluated for lymphedema using the SOAC, the circumference and patient self-
report methods, prevalence differed: 23/145, 45/145 and 25/145, respectively. 
The difference between the four prevalence rates was significant [P <0.001]. Of 
the 28 obese women at baseline, 18 developed lymphedema according to at 
least one of the four measuring methods [P =0.008]. As for the 69 women who 
underwent ALND, almost half (n= 37) had either self-reported lymphedema 
and/or objectified limb swelling. In contrast, SLNB (n=24) resulted in fewer 
patients with lymphedema [P=0.007].  
 
Sensitivity and specificity of lymphedema measurements 
 
Table 1 presents the sensitivity and specificity of the SOAC, the circumference 
and self-report methods using the water displacement method as reference 
measure. The self-report method displayed the highest sensitivity of the three. 
Comparatively, the circumference and the SOAC methods each identified fewer 
women presenting with lymphedema according to the water displacement 
method. The highest specificity was however measured by the SOAC method. 
Moreover, there were several cases in which patients had measured 
lymphedema according to criteria of the SOAC (n=14) or the circumference 
method (n= 36) without having a difference in limb volume greater than 200 mL 
and vice versa (n= 3). 
 
Table 1. The sensitivity and specificity  
 
 
 
  95% CI; 95% confidence interval, SOAC; sum of arm circumference 
 
 
 
Patient perception and measured lymphedema 
 Measurement methods Sensitivity, % (95% CI) Specificity, % (95% CI) 
Circumference 82 (0.48-0.97) 73 (0.65-0.80) 
SOAC  82 (0.48-0.97) 90 (0.83-0.94) 
Self-report  91 (0.57-0.99) 89 (0.82-0.93) 
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We were also interested in the prevalence of women with subjective 
lymphedema. In order to get a wider scope on the problem at hand, we 
combined self-reported complaints of swelling with objective (measured) 
swelling. Table 2 presents patients categorized as follows: no BCRL (no 
subjective complaints and no measured swelling), asymptomatic BCRL (no 
subjective complaints but measured swelling), symptomatic non-BCRL 
(subjective complaints but no measured swelling) and symptomatic BCRL 
(subjective complaints and measured swelling). Once again, the prevalence 
rates varied depending on the diagnostic method used. Interestingly, there were 
women with the perception of arm swelling but without clinical signs of 
lymphedema according to all three methods. However, there were also women 
with clinical signs of lymphedema who did not have self-perceived arm swelling.  
 
Table 2. Patient’s perception and measured lymphedema 
 
BCRL category Water 
displacement 
SOAC Circumference 
No BCRL, % 82 76 63 
Asymptomatic BCRL, % 1 6 20 
Symptomatic non-BCRL, % 10 8 6 
Symptomatic BCRL, % 7 10 11 
 
BCRL; breast cancer related lymphedema, SOAC; sum of arm circumference 
 
 
 
Discussion 
 
In the current study we assessed the prevalence of BCRL at a median time of 
6.2 years after breast cancer surgery. To our knowledge this is the first study 
that used more than one measuring method for describing the long-term 
prevalence of BCRL. A wide point prevalence range of 8-31% was found in our 
data, with the circumference method at prevalence rate of 31% being the 
biggest outlier. In contrast, the water displacement, the SOAC and self-report 
methods yielded point prevalence estimates closer in range, 8-17%. Of the 
scant long-term data that is available, Sagen et al reported a BCRL prevalence 
of 13% measured with the water displacement method five years after breast 
cancer treatment.
20 
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Lymphedema: more than just limb swelling? 
 
Lymphedema constitutes more than just limb volume increase; symptoms that 
patients experience as result of that volume change should therefore also be 
identified. Creating BCRL sub-categories, depicting subjective complaints 
against the different objective measurements, resulted in a better insight on this 
topic.
21, 22
 Symptomatic BCRL was identified in 7% of the patients using the 
water displacement method; this was 10% for the arm circumference method 
and also 10% for the SOAC method. At a follow-up time of five years after 
breast cancer treatment McLaughlin et al reported a prevalence of 5% for 
symptomatic BCRL measured with the circumference method.
14
 We assessed a 
point prevalence double that after a median time of 6.2 years, which is likely 
explained by the fact that our cohort included more women who underwent 
axillary lymph node dissection (47 vs. 36%). Not all patients with self-reported 
complaints of BCRL had clinical measurable signs of limb swelling 
(symptomatic non-BCRL). The discordance seen between patient perceptions 
and measured swelling is consistent with the results reported in other studies.
14, 
23 
A reason why not all of the subjective BCRL complaints might have shown a 
measured increase of limb volume or circumference could be due to the timing 
of the study. Many patients reported to have an increase in complaints after 
more than average exercise and with warm weather. The measurements in this 
study gave an impression of a patient’s lymphedema status at one specific 
moment in time, and thus, cannot exclude the existence of refractory limb 
swelling. Furthermore, symptomatic non-BCRL could also be explained by 
sensory changes in the treated limb due to neurological damage caused by 
axillary surgery or radiation treatment. Vice versa, some women with 
measurable volume and or circumference difference had no subjective 
complaints of pain or swelling (asymptomatic BCRL). An important question is 
whether this BCRL category is clinically relevant; in other words if these 
patients will eventually go on to develop symptomatic BCRL. 
 
Method selection: a matter for consideration 
 
Volumetry is the most reliable method for the assessment of lymphedema, with 
the classic water and the novel optoelectronic (perometer) volumeter forming 
the two methods of choice. Both methods have comparable reliability
24-27
; 
therefore, our selection of the water displacement method was based on cost-
efficiency, the most applied method and readily available device. Even though 
we have used the water displacement method as our gold standard, we believe 
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it to have its shortcomings in cases where minor swelling is accompanied by 
muscle atrophy. This can develop over time when normal use of the affected 
limb is avoided due to lymphedema related symptoms, such as pain and 
heaviness. Minor volume increase in the form of extracellular lymph 
accumulation can be compensated by a volume decrease in muscle mass, in 
which case lymphedema will go undetected. Bioelectrical impedance 
spectroscopy (BIS) on the other hand can accurately differentiate extracellular 
fluid from other tissues and thus solely assess lymph volume by measuring the 
impedance of a spectrum of low frequency electric current passed through a 
body region.
28-30
 It could therefore be argued as to why BIS was not used in the 
current study as the gold standard for BCRL assessment instead of the water 
displacement method. Hayes et al described the short-term prevalence at six 
months after breast cancer treatment using the BIS method as the gold 
standard and the sum of arm circumference and the patient self-report method 
for comparison. 
31
 Importantly, in the early stages of lymphedema swelling is 
refractory and predominately constitutes of extracellular lymph fluid, thereby 
making BIS a suitable tool for diagnosis. 
32-35
 However, as disease progression 
ensues, limb swelling becomes a more permanent entity with the occurrence of 
fibrosis and fat deposition.
36
 As the aim of our study was to assess the long-
term prevalence of BCRL five or more years after breast cancer treatment, 
some lymphedema cases might have already progressed into the chronic 
phase during this period. Thus, the use of BIS instead of the water 
displacement method as the gold standard for the identification of BCRL in this 
study’s setting is not justified. For lack of a more reliable assessment method 
we have accepted the possible limitations of the water displacement method.  
 
Study limitation 
 
A weakness of this study is the fact that it was performed without preoperative 
or direct postoperative baseline measurements; these could have produced a 
more accurate identification of changes in limb volume and circumference. 
Instead, the contra-lateral upper-extremity was used as comparison to 
determine the presence of lymphedema. Differences in circumference or arm 
volume may exist between a woman’s dominant and non-dominant arm. In 
most women these differences are less than 2 cm and therefore not 
significant.
6, 7
 However, slight pre-operative limb volume or circumference 
differences might mask the presence of minor lymphedema in the smaller 
extremity.  
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Conclusion 
 
The prevalence of BCRL more than five years after surgical treatment differs 
depending on the measuring method used. The range of prevalence rates 
observed in this one group of women measured at a single point in time by four 
different methods, underlines the necessity for consensus on the diagnostic 
criteria for BCRL. Currently, there is no single measuring method that can 
identify lymphedema error-free, this is in part due to the changing nature of 
lymphedema. We advise screening breast cancer patients by using a 
combination of subjective complaints and preoperative and sequential 
postoperative limb volume measurements (water displacement method), 
eliminating the chance of missing minor cases of limb swelling. This approach 
will result in more knowledge on the true prevalence of BCRL. Furthermore, the 
efficacy of therapeutic regimens and the design of optimal therapeutic 
approaches can be assessed creating the beginning of an accepted evidence 
based systemic approach of the problem of BCRL. Finally, the implementation 
of a lymphedema screening program will clarify the clinical relevance of the 
asymptomatic BCRL and symptomatic non-BCRL categories.
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Abstract 
 
Aim: To compare the health related quality of life (HRQOL) of long-term breast 
cancer survivors with and without breast cancer related lymphedema (BCRL) 
treated in the sentinel lymph node biopsy (SLNB) era.  
 
Methods: HRQOL was assessed as subject of a secondary analysis of data 
gathered for a study evaluating the prevalence of BCRL in long-term breast 
cancer survivors. The 145 women in this study cohort had undergone SLNB 
and or axillary lymph node dissection (ALND) according to Dutch breast cancer 
treatment guidelines. HRQOL was assessed using two quality of life 
questionnaires: the European Organization for Research and Treatment of 
Cancer Quality (QLQ-C30) and the Breast Cancer-specific Quality of Life (QLQ-
BR23).  
 
Results: Twenty-six women, of whom 5 only underwent SLNB, were identified 
with objectively measured lymphedema and/or self-perceived arm swelling. 
Patients with BCRL scored significantly lower on the social (p=0.000) 
functioning scale after adjustments for BMI and age compared to women 
without BCRL. Compared to normative data, women with BCRL scored 
significantly lower on social- (p<0.001) and role (p=0.001) functioning scales.  
 
Conclusion: HRQOL in long-term breast cancer survivors with BCRL is 
structurally lower than of those without BCRL, even in this small cohort of 
cancer survivors treated in the SLNB-era.  
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Introduction 
 
As a concomitant effect of the increase of the survival rate after breast cancer 
treatment
1
, attention is being shifted towards treatment-related complications 
and their effect on the quality of cancer survivorship.
2-5
 One of the most 
frequent and burdensome complications of breast cancer treatment is 
lymphedema. Breast cancer related lymphedema (BCRL) can develop as a 
result of damage to the lymphatic system brought on by (axillary) surgery and 
adjuvant therapy. BCRL is characterized by an accumulation of fluid in the 
interstitial tissue that causes limb swelling, functional disability, recurrent pain 
and infections and increased psychological distress.
6-9
  
 
Both patients undergoing sentinel lymph node biopsy (SLNB) alone and SLNB 
followed by an axillary lymph node dissection (ALND) are at risk for developing 
upper-limb lymphedema. Despite the efforts of reducing upper-body morbidities 
by the introduction of the SLNB, BCRL rates are still significant. One of the 
largest RCT’s comparing morbidity rates between SLNB and ALND reported a 
fairly high BCRL incidence rate of 7% and a subclinical BCRL rate of 13% after 
three years in patients having undergone SLNB.
10
  
 
The studies published up till now on the health-related quality of life (HRQOL) in 
long-term breast cancer survivors (≥5 years) with BCRL are derived from 
patient cohorts in the pre-SLNB era.
7,11-13
 A HRQOL assessment of 
contemporary patients, in which less invasive axillary surgery is being 
performed more often, is of added value to the available body of evidence. 
Therefore, the aim of this study is to compare the HRQOL of long-term breast 
cancer survivors with and without BCRL in a cohort of women treated in the 
SLNB-era. Furthermore, we will compare the HRQOL of this cohort with 
normative data computed from individuals drawn from the general Dutch 
population. 
 
Patients and Methods 
 
Patients 
 
The HRQOL was assessed as subject of a secondary analysis of data gathered 
for a study evaluating the prevalence of BCRL more than five years after breast 
cancer treatment.
14
 We evaluated the HRQOL of 145 women treated for 
primary unilateral breast cancer at the Maastricht University Medical Centre 
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(MUMC+) between January 2001 and December 2008. Patients were excluded 
in case of disease recurrence, metastases, death and withheld written informed 
consent. Study participants visited the MUMC+ five or more years after breast 
cancer treatment for a one-time clinical assessment. The quality of life 
questionnaires were filled in by the patients themselves. Oncologic and 
treatment-related characteristics of each patient were abstracted from hospital 
records. The hospital’s medical ethics committee approved this study and the 
consent form.  
 
Lymphedema measurements 
 
Arm swelling was assessed using the water displacement method, the current 
gold standard. A home built volumeter was applied according to J. Lette
15
 for 
volume measurements. Both limbs were measured twice, comparing the treated 
side to the untreated side. An arm volume difference greater than 200 ml was 
defined as objective lymphedema. A detailed description of the arm volume 
measurement has been previously published.
14
 
  
Furthermore, participants were asked to indicate the presence of (refractory) 
swelling during a standardized interview by answering the following question 
with a “yes” or “no”: Have you experienced swelling of the upper-limb on the 
breast cancer treated side in the past year? Self-reported lymphedema was 
described as positive if the question was answered with a yes. 
Study participants were divided into two groups: 1) patients with self-reported 
and/or objectively measured arm swelling, 2) patients without arm swelling.  
 
Quality of life measurements 
 
The HRQOL was assessed using the Dutch version of two validated 
questionnaires developed by the European Organization of Research and 
Treatment for Cancer (EORTC): QLQ-C30 version 3.0 and QLQ-BR23 breast 
cancer supplementary module.
16
 Authors received permission from the EORTC 
to use the questionnaires for research purposes. 
  
From the QLQ-C30 questionnaire, the Global Health (self-perceived quality of 
life and health) scale and function scales including physical- (activity in 
everyday life), role- (leisure time  & work life), social- (family & social life), 
emotional- (feelings of worry, depression & irritability) and cognitive 
(concentration & memory) function were used. As for the QLQ-BR23 
questionnaire, we only analyzed the seven questions pertaining to arm and 
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breast symptoms (questions about the presence of symptoms of pain and/or 
swelling in the treated arm and/or breast and the presence of reduced shoulder 
mobility). All of the raw scores were standardized by linear transformation so 
that scores ranged from 0-100, as indicated by the EORTC. A higher score on 
the functioning scale and Global Health scale corresponds with a more healthy 
level of functioning and health.  
 
The QLQ-C30 scores acquired from this study were compared to normative 
values computed from individuals drawn from the general Dutch population.
17
 
This population was designed to be representative of the Dutch-speaking 
population in the Netherlands. While the cohort consisted of men and women, 
we only used the data acquired from the 796 women (mean age of 50.8 years) 
for this study.  
 
Statistical analyses 
 
Statistical analysis was conducted using SPSS for MAC 17.0 (SPSS Inc. 
Chicago, Illinois). Continuous variables were presented as mean and standard 
deviation with mean difference and 95% confidence interval (95% CI). 
Categorical variables were presented in numbers and percentages. The 
differences between groups (BCRL versus no BCRL) were tested using the 
independent-samples t-test for continuous variable and Chi-square test for 
categorical variables. A multivariate analysis was conducted using a model 
containing BCRL and two variables, BMI and age. The analysis was restricted 
to three variables because of the small number of patients in the BCRL group. 
A two-sided p-value ≤ 0.05 was considered statistically significant. 
 
Results 
 
BCRL prevalence 
 
Of the 145 women, 11 (7.6%) were identified to have an arm volume difference 
greater than 200 ml. As for the rate of women with self-perceived arm swelling, 
25 (17.2%) reported to have had swelling in the past year. Almost all (n=10) of 
the participants with objective BCRL also reported self-perceived arm swelling, 
bringing the total of women in the lymphedema group to 26 (17.9%). 
  
Baseline characteristics of the women with BCRL (n=26) and those without 
BCRL (n=119) are presented in Table 1. Women with BCRL were more likely to 
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have a higher BMI at surgery and at follow-up (both p< 0.001), have undergone 
adjuvant chemotherapy (p= 0.003) and hormonal treatment (p= 0.009) 
compared to women without BCRL. Furthermore, they were also more likely to 
have undergone total axillary lymph node dissection (p< 0.001), have more 
positive lymph nodes (p= 0.024) and more total lymph nodes excised (p= 
0.001). Of the 76 women who only underwent a SLNB, 5 (6.6%) met de criteria 
for BCRL versus 21/69 (30.4%) women after ALND. 
 
EORTC QLQ-C30 and QLQ-Br23 scores 
 
Compared to women without BCRL, those with BCRL scored significantly lower 
on the physical functioning (p= 0.003), role functioning (p= 0.008), social 
functioning (p< 0.001), breast symptoms (p= 0.034) and arm symptoms (p= 
0.001) scales (Table 2). We also compared normative QLQ-C30 scores of 
women in the general Dutch population with the scores of the two groups in our 
study. Both the BCRL and no BCRL group scored significantly lower on QLQ-
C30 function scales when compared to the normative scores, but only the 
BCRL group scored statistically lower on the role (p= 0.001) and social 
functioning (p= 0.000) scales (Table 2). Furthermore, women without BCRL had 
a significantly higher Global Health score (p= 0.003) compared to data from the 
normative Dutch population (Table 2).  
 
Multivariate analysis 
 
The statistically significant lower scores for the physical-, role- and social 
functioning scales seen in the BCRL group were further assessed by 
multivariate analysis in order to control for confounding factors. BCRL and BMI 
were independently associated with a decrease in the social functioning scale. 
Standardized coefficients showed a small impact of both BCRL and BMI, β= -
.20, p< 0.05 and β= -.23, p= 0.01 respectively. As for the other two functioning 
scales, after multivariate correction for BMI and age, BCRL was not significantly 
associated with the physical functioning (p= 0.070) nor with the role functioning 
scales (p= 0.17). 
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Table 1. Patient characteristics of those with and without BCRL 
Clinical-factors BCRL 
N= 26 
No BCRL 
N= 119 
Difference between  
means (95% CI) 
P-value 
Age at surgery, mean (SD), in years 55.4 (11.1) 
 
56.5 (11.3) 
 
-1.1 (-3.7 – 6.0) 0.644 
Age at FU, mean (SD), in years 61.6 (11.2) 
 
62.7 (11.2) 
 
-1.1 (-3.7 – 5.9) 0.655 
Time from surgery to FU, mean 
(SD), in months 
77.0 (10.0) 
 
75.6 (9.6) 
 
1.4 (-5.5 – 2.8) 0.523 
BMI (kg/m
2
) at surgery, mean (SD)  30.3 (6.2) 
 
25.1 (4.0) 
 
5.2 (-7.2 – -4.7) < 0.001 
BMI (kg/m
2
) at FU, mean (SD) 31.6 (6.8) 
 
25.4 (4.1) 
 
6.2 (-8.1 – -4.1) < 0.001 
Tumor status, no (%) 
         Tis – TI 18 (69.2) 99 (83.2)  0.109 
         TII – TIV 8 (30.8) 20 (16.8)  
Breast surgery, no (%) 
        Mastectomy 9 (34.6) 25 (21.0)  0.199 
        Lumpectomy 17 (65.4) 94 (79.0)  
Axillary surgery, no (%) 
        SLNB 5 (19.2) 71 (59.7)  < 0.001 
        ALND 21 (80.8) 48 (40.3)  
Total nodes excised, mean (SD)  12.3 (7.6) 7.0 (7.2) 5.3 (-8.4 – -2.2) 0.001 
Total positive nodes excised, mean 
(SD)  
2.1(2.7) 
 
0.8 (2.5) 
 
1.3 (-2.3 – -0.2) 0.024 
Dominant arm is affected, no (%) 12 (46.2) 
 
59 (49.6) 
 
 0.752 
Post-menopausal, no (%) 18 (69.2) 77 (64.7)  0.660 
Adjuvant Therapy, no (%) 
     Rtx (Breast / loco regional) 19 (73.1) 90 (75.5)  0.785 
     CHtx 18 (69.2) 44 (37.0)  0.003 
     Htx 20 (76.9) 58 (48.7)  0.009 
SD; standard deviation, no; number, FU; follow-up, BMI; body mass index, SLNB; sentinel lymph 
node biopsy, ALND; axillary lymph node dissection, RT; radiotherapy, CHtx; chemotherapy, Htx; 
hormone therapy  
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Table 2. QLQ-C30 & QLQ-BR23 scores of patients with BCRL, without BCRL and in the general Dutch population 
 * p <0.05, **p<0.01, ***p≤ 0.001, 95% CI; 95% confidence interval, BCRL; breast cancer related lymphedema
EORTC BCRL 
(n=26) 
No BCRL 
(n=119) 
Normative data 
(n=796) 
BCRL VS no BCRL BCRL VS normative 
data 
no BCRL VS normative 
data 
QLQ-C30, mean (SD)    
Difference between 
means (95% CI) 
Difference between 
means (95% CI) 
Difference between 
means (95% CI) 
Global Health status 
78 (18) 
 
83 (16) 78 (17) -5 (-12 – 2) 0 (-7 – 7) 5 (2 – 8)** 
Physical function 
73 (17) 
 
84 (18) 90 (15) -11 (-19 – -4)** -17 (-23 – -11)*** -6 (-9 – -3)*** 
Role function 
75 (28) 
 
88 (21) 89 (21) -13 (-22 – -3)** -14 (-22 – -6)*** -1 (-5 – 3) 
Emotional function 
79 (20) 
 
80 (19) 89 (16) -1 (-9 – 7) -10 (-16 – -4)*** -9 (-13 – -6)*** 
Cognitive function 
78 (24) 
 
82 (19) 92 (15) -4 (-13 – 5) -14 (-20 – -8)*** 10 (-13 – -7)*** 
Social function 
81 (23) 
 
94 (14) 94 (16) -13 (-20 – -16)*** -13 (-19 – -7)*** 0 (-3 – 3) 
QLQ-BR23, mean (SD)     
Breast symptoms 
18 (17) 
 
11 (15)  7 (-13 – -1)*   
Arm symptoms 
36 (28) 
 
14 (18)  22 (-31 – -13)***   
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Discussion 
The aim of this study was to assess the HRQOL of long-term breast cancer 
survivors with BCRL using the EORTC QLQ-C30 and BR23 questionnaires. 
After adjustment for BMI and age, the women with BCRL scored lower on the 
social functioning scale when compared to the women without BCRL. 
Moreover, the presented cohort as a whole scored lower on a majority of the 
functioning scales compared to that of the general Dutch population, but it was 
only the BCRL group that scored significantly lower on role- and social 
functioning.     
  
Our findings are in line with other studies reporting on the impact of BCRL on 
the HRQOL in long-term breast cancer survivors (≥ 5 years). The available 
studies are few, but all to some degree show functional impairment (Table 3). 
An important point to address is the fact that the patients in these long-term 
studies were largely included prior to the implementation of the SLNB. Almost 
all of the women in these studies underwent ALND. To our knowledge, this is 
the first study reporting on the HRQOL of long-term breast cancer survivors with 
BCRL depicted in the SLNB-era. It is known that ALND is associated with a 
higher risk of objective and subjective upper-limb morbidities compared to 
SLNB, resulting in a higher risk of impaired HRQOL.
18-22
 In the current study we 
simply assessed the influence of BCRL on the HRQOL, not regarding the 
possible effect of other upper-limb morbidities such as pain, decreased range of 
motion etc. Half of the women in this cohort underwent a SLNB (76/145). Of 
these 76 women, five were in the BCRL group, which equals to a 6.6% rate in 
the SLNB patients. This incident rate fits well into the 3%-23% BCRL incident 
range reported after SLNB in a review of procedure specific incidence rates of 
BCRL by Shah et al.
23 
 
  
The cohort of breast cancer survivors presented with a statistically significant 
higher Global Health score as compared to the normative population, meaning 
that breast cancer survivors were more satisfied with their general health and 
quality of life than healthy women. This observation, also known as the 
“response-shift phenomenon”, has been described in previous publications 
reporting on the quality of life in long-term breast cancer survivors.
3
 The history 
of illness could have caused the patient to redefine her concept of quality of life 
and therefore being more satisfied.
24
 That said, women with BCRL in this study 
nevertheless suffered from an impaired functioning, with respect to social and 
role functioning. 
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In light of the recent publication of the ACOSOG-Z0011 trial, the role of ALND 
performed currently with the aim of maintaining regional nodal control is being 
questioned. Results of this trial demonstrated no survival benefit in sentinel 
node positive (1-2 nodes) patients undergoing breast-conserving surgery in 
combination with radiation therapy randomized to undergo additional ALND as 
compared to those randomized not to.
25
 It is expected that the next generation 
of trials will provide more insight on the matter, which as a consequence might 
eventually lead to fewer indications for ALND in the future. The authors of the 
present study are of the opinion that regardless of this, BCRL will remain a 
clinically relevant morbidity of the upper-limb as demonstrated by the BCRL 
incident rates after SLNB.
6,23 
 
Several limitations should be considered in this study. Firstly, not all potential 
sociodemographic and psychological confounders were recorded. We were not 
able to control for the potential confounding effects of anxiety/ depression
21
, 
lack of social support
26 
and coping mechanisms
27
 to name a few, as they have 
shown to play an important role in predicting the HRQOL. Secondly, the power 
was low due to a small number of subjects in the lymphedema group, this 
causing us the limit the use of variables to three for the multivariate analysis.  
 
Conclusion 
 
In conclusion, our findings indicate that the HRQOL in breast cancer survivors 
with BCRL is structurally lower than of those patients without BCRL, even in this 
small cohort of cancer survivors treated in the SLNB-era.  
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Table 3. Overview of HRQOL assessment studies in long-term breast cancer survivors with and without BCRL 
Ref. Population Time since 
surgery  
BCRL definition HRQOL assessment 
7 
 
N=245, cross-sectional study.  
Inclusion: 1985-1991. 
Axillary surgery: 100% underwent 
ALND 
Ranging 9.4-
16.5 years 
Self–report of swelling BCRL (n=75) VS no BCRL  
SF-36: Severe swelling & activity limiting swelling 
each significantly associated with worse physical 
function. 
 
11 N=1287, population based study. 
Inclusion: 1986-2003. 
Axillary surgery: not provided 
Mean 8.1 SD 
0.2 years 
Self-report of BCRL 
diagnosis 
BCRL (n=104) VS no BCRL or arm symptoms  
SF-36: significantly ↓scores for all scales except 
mental health & role limitations emotional 
subscale. 
 
12 N=990, prospective study. 
Inclusion: 1996 -1998. 
Axillary surgery: 93% underwent 
ALND 
5 years Self-report of swelling 
and/ or limitations in 
arm movement (arm 
problems) 
Arm problems (n= not provided) VS none 
EORTC QLQ-C30: arm problems scored 
significantly lower on Global Health & all 
functioning domains.  
13
)
 N=151, retrospective cohort study. 
Inclusion: 1986-2000.  
Axillary surgery: 100% underwent 
ALND 
Mean 4.8 SD 
0.2 years 
Volume difference ≥ 
200cm
3
 between 
operated and non-
operated limb 
BCRL (n=42) VS no BCRL  
FACT-B: BCRL significantly associated with 
decreased emotional-, functional-, physical-, and 
breast well-being. 
Current 
study 
N=145, cross-sectional study. 
Inclusion: 2001-2008 
Axillary surgery: 48% underwent 
ALND 
Mean 6.2 SD 
0.81 years 
Self-report of swelling 
and/or volume 
difference ≥ 200cm
3
 
between operated and 
non-operated limb 
BCRL (n=26) VS no BCRL 
EORTC QLQ-C30: BCRL significantly associated 
with decreased social functioning. 
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Abstract 
Background: Biomechanical skin changes in breast cancer related 
lymphedema (BRCL) have barely been described and objectively tested. This 
study aims to compare the skin of upper-limb lymphedema with skin of the 
healthy contralateral arm, in order to demonstrate changes of elasticity, visco-
elasticity and level of hydration of the skin in BCRL. The secondary aim is to 
investigate the correlation between biomechanical skin changes and 
measurements that are currently used in clinical practice, such as volume 
measurement and Lymph-ICF score.  
Methods and Results: Eighteen patients with BCRL and 18 healthy individuals 
were included in the study. A Cutometer® was used for measurements for skin-
elasticity and visco-elasticity, a Corneometer® was used for measurements of 
skin-hydration. Measurements of both test groups were compared. In BCRL 
patients, there was a significant difference (p=<0,028) between the elasticity of 
the skin of the lymphedema arm compared to the healthy contralateral arm. 
There were no significant differences for level of skin-hydration or visco-
elasticity in lymphedema patients between the measurements on the skin of the 
lymphedematous and healthy arm. In healthy individuals, there were no 
significant differences for all measurements between skin of both arms. 
Spearman’s correlation was significant (p = <0,01) for difference in volume and 
difference in elasticity in BCRL patients.  
Conclusion: This study shows an impaired elasticity for the skin of the lower 
arm in patients with lymphedema compared to the contralateral healthy arm. 
Promising evidence is suggested for the use of the Cutometer device in the 
diagnostic evaluation of BCRL. 
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Introduction 
One of the most underestimated and debilitating morbidities breast cancer 
survivors may experience is breast cancer related lymphedema (BRCL). BCRL 
may present with symptoms of heaviness, tightness and pain. It is a result of 
the accumulation of lymphatic fluid in the interstitial tissues and is characterized 
by swelling of the arm, hand, breast and/or trunk. In the initial stage of 
lymphedema, the edema may be soft and pitting.  If left untreated, the reaction 
to tissue injury induces the accumulation of inflammatory cells, which is a 
hallmark of pathophysiological events in the skin. Activation of lymphocytes, 
leukocytes and release of cytokines induce connective tissue synthesis in 
fibroblasts. The excessive deposition of extracellular matrix, especially 
collagens, is the complex tissue response which is called fibrosis.
3
 
Ultrastructural research has shown that this process is accompanied by the 
degeneration of smooth muscle cells in the lymphedematous tissue.
4
 The 
contraction of these smooth muscle cells, together with the compression of 
skeletal muscles, determine the interstitial pressure that stimulates lymphatic 
drainage. The above-described pathological changes of the lymphedematous 
tissue can be regarded as a key step for the progressing pathological status of 
lymphedema.
5, 6
   
Tissue resistance in post-surgical lymphedema has previously been measured 
and evaluated with the use of tonometry.
7
 Indentation measurement on 
lymphedema patients has shown increased tissue resistance in 
lymphedematous skin.
8, 9
 Both the pathogenesis of BCRL and the previous 
findings of increased tissue indentation in lymphedatous tissue, implicate a role 
of biomechanical skin changes within development of BCRL.   
The Cutometer device is seen as an attractive and suitable option for testing 
and monitoring changes in biomechanical properties of the skin
10, 11
. This 
device has been used in previous research for the evaluation of skin properties 
in facial wrinkles, wounds and scar healing.
12-14
 Furthermore, it has been used 
for measuring elasticity of the skin after radiotherapy.
15
 Besides the 
biomechanical skin properties in the evaluation of BCRL, fluid accumulation is 
an initial component in edematous and lymphedematous conditions. Tissue 
fluid water and proteins accumulate in the interstitial space,
16, 17
 this makes it 
both of fundamental and clinical interest to know what relationship exists 
between tissue water and tissue resistance.     
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Local tissue water in lymphedema has already been quantified using the 
tissue’s dielectric constant (TDC), showing significantly greater values in 
lymphedematous legs compared to healthy legs.
9
 These outcomes gained our 
interest for determining skin hydration in lymphedematous conditions. In the 
past, measurements of skin hydration have particularly been used in 
dermatologic testing of products and for the evaluation of skin development.
18-20
 
Measurements are mostly performed by use of a Corneometer, which is a 
validated tool for measuring hydration of the stratum corneum of the skin.
 20
 
The primary aim of this study is to compare the lymphedematous skin to that of 
the healthy contralateral arm in breast cancer survivors, in order to demonstrate 
the biomechanical changes (elasticity, visco-elasticity) and level of hydration of 
the skin. The secondary aim is to correlate biomechanical skin changes with 
current clinical assessment measurements of lymphedema, such as objective 
volume measurement as well as subjective functional impairments measured 
with the Lymph-ICF score. 
 
Materials and Methods 
Subjects 
A total of 34 women with BCRL were asked to participate in the study, of which 
24 were willing to participate. All subjects were over 18 years and were treated 
for unilateral early stage breast cancer in Maastricht University Medical Centre+ 
(MUMC+) between May, 14
th
 2004 and December 21
st
, 2010. During routine 
follow-up visit after primary breast cancer surgery, upper-limb volume of the 
affected side was measured with the water-displacement method and 
compared to that of the healthy contralateral arm. Patients were enrolled in the 
study if they had more than 200 milliliters (ml) volume difference and had 
subjective complaints or if they were currently being treated by a lymphedema 
therapist. Patients were excluded from participation if they had, recurrent breast 
cancer, bilateral breast cancer, distant breast cancer metastases, or if they had 
a medical history of cancer other than breast cancer. A total of 22 patients met 
the inclusion criteria. Subjects were instructed not to wear elastic arm garments 
on the test day so that volume measurements were not influenced. Written 
consent was obtained from each subject prior to inclusion of this study.  
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Eighteen healthy participants, all women, without BCRL or open lesions on their 
upper extremity were asked to participate. Three subjects with unilateral BCRL 
wore an elastic arm garment on the test day (against the given instructions). 
One patient exceeded the maximum arm volume measurable by the water 
displacement method. These four BCRL patients were excluded from the study 
before calculations were made.  
Ultimately 36 subjects completed the study, 18 subjects with unilateral BCRL 
and 18 healthy individuals. Baseline characteristics of all subjects were 
collected before testing.  
Study design 
All subjects were invited for a single consultation in the outpatient clinic of 
MUMC+. Measurements were done in the same room with specified conditions; 
a temperature of 20-22ºC and 40-60% humidity as instructed in the measuring 
principles of the Cutometer® MPA 580 (Courage and Khazaka, Köln, 
Germany). Patients were seated with their arm on the surface of the table with 
their hand and fingers relaxed during Cutometer measurements. The angle of 
the elbow was approximately 120º, the angle between the upper arm and the 
supporting surface was approximately 40º, and the angle between the upper 
arm and the shoulder was approximately 90º. Measurements for elasticity, 
visco-elasticity and hydration were performed on each subject on both arms. 
      
Elasticity measurements were taken of the skin of both lower arms, at the volar 
midpoint between the tip of the ulnar styloid process and medial epicondyle of 
the humerus (F-MP). This is one of the predetermined sites of the lower arm 
where extra lymphatic fluid of the upper-limb can accumulate.
21
 The volar site of 
the arm was taken so that measurements were not influenced by body hair on 
the dorsal site of the arm.  Cutometer measurements were repeated after ten 
minutes, as advised by the device manufacturer. The suction and release time 
of the Cutometer could cause the skin to be strained and might distort the 
results of the next measurement. The average of both measurements was 
taken and used for analysis.      
    
All study procedures were in accordance with the ethical standards of the 
Medical Ethical Committee Maastricht and with the Helsinki Declaration of 
1975, as revised in 2008. 
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Elasticity and visco-elasticity of the skin 
Vertical extensibility of the skin was measured using a Cutometer MPA 580 
system with a Cutometer Q probe; a non-invasive suction device that measures 
the vertical deformation of the skin surface. A constant negative pressure of 
450 mbar during 6 seconds was applied, to draw the skin up into the circular 
aperture (6mm diameter) of the probe, followed by normalization of the 
pressure and returning of the skin in original shape.
22
 The Cutometer device 
generates a graph showing skin extensibility (Ue), delayed distension (Uv), final 
deformation (Uf), immediate retraction (Ur) and final retraction (Ua). (Figure 2)  
The Cutometer software MPA 580 was used to automatically generate R 
parameters (R0 to R9). These parameters are relative parameters which are 
thought to be independent on skin thickness, which varies in age, sex and 
anatomical region.
11
 Skin elasticity is reflected by R2, R5 and R7. 
23
 These 
values were generated as follows (figure 2): R2 (Ua/Uf) (gross elasticity), R5 
(Ur/Ue) (net elasticity) and R7 (Ur/Uf) (biological elasticity). Value R6 (Uv/Ue) 
represents the viscoelasticity ratio.  
Hydration of the skin 
An additional Corneometer CM 825 probe was used to assess the level of 
hydration of the stratum corneum in the lymphedema and healthy contralateral 
arm. The probe contains a grid of electrodes, which are used for measuring the 
capacitance of the electrodes and epidermal skin to calculate total skin 
capacitance. The values of capacitance of the skin are converted in the 
instrument in arbitrary units of skin hydration ranging from 0 to 120.
18
 
Calibration was performed using a cellulose filer paper saturated with a 15% 
NaCl aqueous solution, giving a maximal hydration value of 120. To increase 
reliability, measurements at F-MP on both arms were taken three times from 
which the average was taken. 
Determining severity of lymphedema 
The degree of lymphedema is determined by different measurements and 
values, including volume difference of the upper-limb and experienced 
disabilities as a result of the lymphedematous limb.
24, 25
 All lymphedema 
patients in the study underwent an objective measurement of volume of both 
arms, and had to fill-out the Lymphedema Functioning, Disability and Health” 
(“Lymph-ICF”) questionnaire for evaluation of the current functional impairments 
they were experiencing from the lymphedema.      
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The Lymph-ICF is a validated questionnaire that assesses the impairments in 
function, activity limitations and participation restrictions in patients with upper 
limb lymphedema, based on 29 questions corresponding with a score between 
0-100. A higher score indicates more problems with functioning related to 
upper-limb lymphedema.
26
        
Inter-limb volume difference measured using the water displacement method, 
the golden standard for measuring arm volume.
25
  A Volumeter (Varitex, 
Haarlem, The Netherlands) was filled with tap water with a temperature of 25 
°C and 32 °C. Water temperatures across the range of 20 to 32 degrees 
Celsius were not found to affect the volume measured.
27, 28
 A circumference line 
was drawn at 80% of the arm length, measured from the tip of the third digit to 
the tip of the acromion.  Subjects were instructed to lower the arm into the 
Volumeter until the water reached the circumference line. The Volumeter 
weighed the overflowing water with an integrated calibrated scale with an 
accuracy of 1cc. All water displacement measurements were done after 
hydration measurements with the Corneometer CM 825 probe, so that the 
hydration state of the stratum corneum of the skin could not be influenced by 
the water exposure of the arm in the Volumeter. 
Data analysis 
Patients and clinical characteristics were described using descriptive statistics. 
Reliability analysis was used to calculate intraclass correlation coefficient (ICC) 
to determine the intra-rater reliability of the Cutometer measurements in the 
lymphedematous arm. The Intraclass Correlation Coeffeicient (ICC) was used 
to determine the intra-rater reliability of all elasticity measurements in healthy 
and lymphedema skin. Intra-rater reliability was determined from two repeated 
measurements with the Cutometer done by the same investigator. To assess 
differences between biomechanical skin properties in both arms, a Paired 
Samples t-test was used. A p-value of <0,05 was considered statistically 
significant.  
 
The measurement parameters (elasticity or hydration) that were significantly 
different in the BCRL arm and the healthy contralateral arm, were correlated to 
clinical assessment points (difference in limb volume and lymph-ICF score). 
These correlations were calculated with Spearman’s correlation coefficient.  
Data were analyzed using statistical software (SPSS 20.0 Inc Chicago, Ill).  
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Results 
Participants 
All 36 subjects were able to complete the study. BCRL patients had a median 
age of 63 years [SD 9,2]. Ten patients had left-sided lymphedema, 8 patients 
had right-sided lymphedema. Healthy individuals had a mean age 23 [SD 12,4] 
of and a mean BMI of 22 [2,7]. All 18 individuals were female. Patient 
characteristics of both groups are described in Table 1. 
 
Table 1. Patient characteristics 
Healthy individuals (N=18) BCRL Patients (N=18)
Patient Characteristics Mean [SD] n=18 (100%) Mean [SD] n=18 (100%)
Age (years) 23 [12,4] 63 [9,2]
BMI (kg/m²) 22 [2,7] 27 [5,1]
Right-handed N (%)  17 (94,4%) 16 (88%)
Smoking N (%) 2 (11,1%) 2 (11,1%)
Lymphedema 0 (0%) 21 (100%)
Arm volume difference (cc)  - 385 [369,1]
Lymph-ICF score  - 36 [19,5]
Right- sided lymph edema N (%)  - 10 (55,5%)
Dominant-hand lymph edema N (%)  -  8 (44,4%)
 
Reliability of measurements 
Intraclass correlation coefficients (ICC) for all elasticity parameters were high, 
namely: 0,707 for biological elasticity (R7), 0,715  for net elasticity (R5) and 
0,882 for gross elasticity (R2). ICC for viscoelasticity (R6) was 0,753.  
 
Interlimb difference – elasticity and viscoelasticity 
Patients with BCRL had an impaired elasticity of the skin in the lower 
lymphedematous arm, compared to their healthy contralateral arm. All values 
for elasticity showed a significant difference. (R2: p= 0,028; R5: p=0,019; R7: 
p=0,013). The mean elasticity difference between both arms ranged from 0,127 
(R5) to 0,08 (R7). There was no significant difference between viscoelasticity of 
the lymphedematous arm and contralateral healthy arm (R6: p=0,409). Healthy 
individuals showed no difference for values of elasticity and visco-elasticity 
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between the skin of both lower arms (R2: p= 0,782; R5: p=0,339; R7: p=0,147 
and R6: p=0,632). (Table 2) 
Interlimb difference – hydration 
The hydration of the skin between both arms was not significantly different in 
BCRL patients (p=0,218). In healthy individuals, the difference was also not 
significant (p=0,488) (Table 2). 
 
Table 2. Difference in skin properties in healthy individuals and BCRL patients
Healthy individuals (N=18) BCRL patients (N=18)
Arm difference 
Mean T Mean T
Lower Upper Lower Upper
Hydration 0.611 ‐1.207 2.429 0.709 0.488 2.596 ‐1.685 6.877 1.28 0.218
Elasticity
R2 ‐ gross elasticity 0.002 ‐0.015 0.020 0.281 0.782 0.085 0.010 0.159 2.404 0,028*
R5 ‐ net elasticity 0.023 0.023 0.026 ‐0.983 0.339 0.128 0.024 0.238 2.591 0,019*
R7 ‐ biological elasticity 0.006 ‐0.031 0.019 ‐0.488 0.632 0.082 0.020 0.144 2.779 0,013*
Viscoelasticity
R6 ‐  visco‐elasticity 0.030 ‐0.071 0.012 ‐0.519 0.147 ‐0.026 ‐0.091 0.039 ‐0.846 0.409
Paired sample t-Test, * significance level <0.05
95% confidence 
interval
95% confidence 
interval
Sign 
(2‐tailed)
Sign  
(2‐tailed)
Interlimb difference – volume 
Mean difference for volume between both arms in BCRL patients was 385cc 
[SD 369]. 
Lymph – ICF score 
Mean Lymph-ICF score for BCRL patients were 36 [SD 19,5]. 
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Correlations (between biomechanical skin changes and volume difference 
or Lymph ICF score) 
Spearman correlations for inter-limb differences in elasticity (R2, R5 and R7) 
and inter-limb volume difference were significant for R2: r = 0,591 (p = 0,010); 
R5: r = 0,618 (p = 0,006) and R7: r = 0,649 (p = 0,004) (Figures 1,2,3). 
Correlation coefficients for elasticity and Lymph-ICF score were low and not 
significant, ranging from r = 0,031 (R7) to r = 0,088 (R2).  
 
 
Figure 1. Correlation between elasticity difference (R2) and volume difference (cc) 
between both arms.
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Figure 2. Correlation between elasticity difference (R5) and volume difference (cc) 
between both arms. 
 
Discussion 
The results of this study show a significantly lower elasticity of the skin in upper-
limb lymphedema. This finding is supported by the theory that there is an 
increase in volume of the subcutaneous tissue which affects the skin by 
increasing its tension at rest.
24
 The proportional changes within the tissue result 
in modification of the intermolecular bridging and thickening of the collagen 
bundle. 
30
    
The Cutometer device revealed to be a reliable method for the evaluation of 
skin elasticity in lymphedematous skin using the suction method. Values for 
extensibility and elasticity were reliable with a reproducibility ranging from 0,707 
to 0,882. Other studies using a Cutometer for measuring skin properties found 
small coefficients of variation between measurements ranging from 0,7%-
6,2%.
10, 31
 Inter-relation parameters for elasticity measurements show high 
correlations. (R: 0.7 -  >0,9).
32
 The advantage of measurements with the 
Cutometer is that the outcome for elasticity is corrected for the depth of 
deformation applied with the instrument. The small size of the measuring probe 
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makes it very applicable in clinical practice. In addition, the minimal measuring 
diameter decreases the chance of bias due to topographical irregularities. 
 
Figure 3. Correlation between elasticity difference (R7) and volume difference (cc) 
between both arms.  
 
 
Tools that have previously been used for the measurement of biomechanical 
properties of the skin are a Tonometer or a caliper. A tonometer can be applied 
to the skin and measures the depth of the mass that is descended. Results of 
measuring with the tonometer highly relied on the correct positioning and 
amount of pressure applied when placing the tool on the skin. 7, 33 A caliper, 
which is used to measure skin creases of the arm, appeared to be a reliable 
measuring method, but edema of the deeper tissues is not taken into account. 
34 Tissue indentation measurements for the assessment of lymphedema have 
previously been developed to evaluate tissue resistance. Tissue resistance is 
not only dependent on the biomechanical properties of the skin, but also 
influenced by the underlying accumulated interstitial water.
9
 The amount of 
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interstitial water can be easily influenced by therapy such as manual lymphatic 
drainage. Indentation measuring is therefore not suitable for quantifying the 
biomechanical properties of the skin alone. Measurements with the Cutometer 
are less dependent on the amount of interstitial water, as it measures only the 
skin extensibility with use of the suction method. This can make the 
measurement very suitable for diagnostic of follow-up measurement in clinical 
practice to investigate the pathological changes of the skin in BCRL. 
         
There are a few other studies that use a Cutometer for measuring skin 
extensibility and elasticity in lymphedematous skin. Auriol et al. showed a 20% 
reduction of skin extensibility (Ue) and elasticity (R5) in the lymphedema lower-
limb in comparison to its healthy contralateral limb.
34
 These results are 
consistent with our findings of an impaired elasticity in the skin of upper-limb 
lymphedema. In addition, the current study shows a significant correlation 
between elasticity- and volume difference of both arms. This suggests a clinical 
relevance for the elasticity parameter. In other words: a continued decrement in 
the elasticity parameters may be an indication for further progression of 
lymphedema.      
Lymphedema evaluation in clinical practice tends to focus on volume change. 
Although volume is important and is the most objective current clinical measure, 
using only volume may overlook important tissue texture changes, as well as 
latent stage lymphedema disease. 
29
 Hacard et al. set up a study with patients 
undergoing therapy for lymphedema, and used values of elasticity measured 
with a Cutometer to evaluate the changes in skin properties before and after 
therapy.
23
 Correlations were calculated for elasticity parameters and decrease 
of volume after therapy. A correlation was not found. This could be explained by 
the fact that in severe stages of lymphedema, where skin fibrosis and 
accumulation of extracellular matrix occurs
3
,
 
elastic fibers might be destroyed. 
The elasticity parameter is therefore probably not applicable for a solitary 
follow-up measurement after treatment. However, elasticity parameters might 
be very useful in the late stages of lymphedema where fibrosis of the skin 
occurs despite a constant volume of the limb.    
     
Considering that a relatively small population group is used in this study, 
individual patients might have had a big influence on results and significance. If 
elasticity parameters are to be used as a follow-up or diagnostic tool in clinical 
practice, research should be further carried out in a prospective setting with 
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more patients in different stages of lymphedema and measurements taken 
before and after lymphedema treatment. Subgroup analyses can then be 
performed to investigate for which purposes in clinical practice the Cutometer 
measurements are most relevant.      
Our Corneometer measurements showed no significant differences for levels of 
hydration in the lymphedematous arm compared to the contralateral healthy 
arm. This is explained by the fact that the Corneometer mainly measures the 
hydration state of the stratum corneum of the skin.
35
  
Fluid in lymphedema usually accumulates in the subcutaneous tissue of the 
arm, which cannot be measured on the skin surface. Measurements with use of 
tissue’s dielectric constant (TDC) have shown a significantly higher amount of 
local tissue water in lymphedematous arms when compared to healthy arms or 
arms of breast cancer patients prior to surgery. 
36, 37
TDC measurement might 
therefore be more suitable for assessing local tissue water in BCRL then the 
Corneometer measurement.  
Conclusion 
In this article a new method for measuring skin-elasticity of upper-limb 
lymphedema is proposed. This study showed an impaired elasticity of the skin 
of the lower arm in lymphedema compared to the contralateral healthy arm. 
There is no significant difference in elasticity in skin of both arms in healthy 
individuals. This study reports promising evidence for the use of Cutometer 
device in the evaluation of BRCL. Further research is planned which includes a 
larger population in a prospective setting in subgroups for different stages of 
lymphedema, so subgroup analyses can be performed. The use of the 
Cutometer as a diagnostic or follow-up tool in clinical practice can then be more 
extensively evaluated. 
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Abstract 
 
Aim: To determine if breast reconstruction has an influence, either protective or 
risk increasing, on the prevalence of breast cancer related lymphedema 
(BCRL).  
 
Methods: Women who underwent unilateral mastectomy and axillary lymph 
node dissection (ALND) with or without immediate or delayed breast 
reconstruction between January 2006 and December 2010 were included. 
BCRL was defined as subjective complaints of arm swelling accompanied by an 
inter-limb volume difference of >200ml or receiving treatment for arm 
lymphedema.  
 
Results: A total of 130 women were included. Breast reconstruction (n= 59) 
was performed with a tissue expander or implant in 26 cases, with an 
autologous free flap in 29 cases and with a combination of an implant and 
latissimus dorsi myocutaneous flap in 4 cases. The prevalence of BCRL was 
45% (32/71) in the mastectomy only group and 19% (11/59) in the 
reconstruction group (p=0.001). After multivariable adjustment breast 
reconstruction was associated with a significantly lower BCRL risk (OR=0.30; 
95% CI 0.13 – 0.72).  
 
Conclusion: BCRL was less frequently observed in patients undergoing breast 
reconstruction after mastectomy and ALND. Further studies are needed to 
confirm this association of breast reconstruction with BCRL. This information is 
of interest for the surgical decision making process.  
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Introduction 
Breast reconstruction, either with an implant or tissue flap, has become an 
indispensible addition to breast cancer management. Not only do modern 
reconstructive techniques provide good aesthetic results, they also have been 
demonstrated beneficial with regards to quality of life and body image
 1,2 
without 
interfering with cancer management.
3, 4
 The wide application of reconstructive 
breast surgery has raised the question whether it should be considered as a 
risk factor or protective factor for the development of breast cancer related 
lymphedema (BCRL). The current literature provides some evidence for a 
protective effect of breast reconstruction, autologous and implant based, on the 
development of BCRL.
5-7
        
Breast reconstruction is an important component of rehabilitation after ablative 
breast surgery. In cases where breast-conserving surgery is impossible due to 
tumour size, mastectomy followed by an immediate or delayed reconstruction is 
optional. These procedures do not only provide good aesthetic results, but have 
also been demonstrated beneficial with regards to quality of life and body 
image
1 – 4 
without interfering with cancer management.
5, 6
 Hence, it is evident 
why breast reconstructions have become an indispensible addition to breast 
cancer management.         
Arm lymphedema is one of the most burdensome breast cancer treatment 
related complications.
7, 8
 Breast cancer related lymphedema (BCRL) can occur 
when local lymphatic vessels are damaged, causing fluid stasis that manifests 
as arm swelling and structural tissue changes.
9, 10
 Some treatment modalities 
are notorious lymphedema risk factors, namely chemotherapy, radiation 
therapy and axillary surgery.
11 – 13
 The question whether reconstructive breast 
surgery should be added to the list of risk factors has lead to an increased 
interest in the role of this commonly performed surgery within the context of 
breast cancer treatment. The current literature bears some data on the role of 
breast reconstruction, autologous and implant based, on the development of 
BCRL.
14 – 18
     
The aim of this study was to determine the impact of reconstructive breast 
surgery on the development of BCRL by comparing the prevalence rate of 
BCRL in breast cancer survivors who only underwent mastectomy and of those 
with an additional breast reconstruction. 
 
Lymphedema prevalence and reconstructive breast surgery 
 72 
 
Methods 
Patients 
We retrospectively identified all women who underwent a unilateral mastectomy 
with or without breast reconstruction for primary breast cancer between January 
1
st
 2006 and December 31
st
 2010 in one university hospital, Maastricht 
University Medical Centre+, and two neighbouring community hospitals, Orbis 
Medical Centre in Sittard and VieCuri Medical Centre in Venlo. Approval for the 
study was obtained from the Medical Ethics committee of the Maastricht 
University Medical Centre+. Information on the surgical procedures (oncological 
and reconstructive), tumour characteristics and adjuvant medical treatment was 
extracted from hospital medical records. Patients who had died or who were 
alive with recurrent/metastatic disease or contralateral breast involvement were 
excluded. The remaining 692 women were contacted via mail and were asked 
to take part in a one-time medical examination and standardized interview. Two 
hundred ninety two (42%) agreed to participate. However, 9 were excluded 
secondarily, 5 because recurrent disease had developed and 4 because 
bilateral disease had been treated, resulting in a study population of 283 
women. For this study, only those 130 patients were selected who had 
undergone a full axillary lymph node dissection, as this is known to be the most 
important risk factor for developing BCRL. The 153 women who either had no 
axillary surgery (n=7) or only underwent sentinel lymph node biopsy (SLNB) 
(n=146) were excluded from analyses. 
Study procedures 
The participants were interviewed and examined by the chief investigator (TLP) 
with assistance of two dedicated researchers (NH, CI).  
1. Standardized interview 
A standardized interview was conducted using a lymphedema risk assessment 
questionnaire, which was specifically developed for the purpose of the study. 
This questionnaire includes questions on post-operative seroma formation, 
history of an episode(s) of erysipelas in the affected arm since surgery and 
history of injury (bone fracture and/or distortions) of the affected arm since 
mastectomy. Furthermore, each patient was asked to indicate the presence of 
subjective swelling by answering the following question with a “yes” or “no”: 
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Have you experienced swelling of the upper-limb on the breast cancer treated 
side in the past year?  
2. Clinical examination 
The patients’ bodyweight and height were measured in order to determine the 
body mass index (BMI kg/m
2
). This was followed by a clinical examination of 
the chest wall and upper limbs, in which information on limb symmetry, skin 
texture/ thickness/tension and the aspect of surgical scar(s) was documented. 
Lastly, bilateral limb volume was assessed using the water displacement 
technique.
19
 BCRL was defined as subjective complaints of arm swelling 
accompanied by an inter-limb volume difference of >200ml or if the patient was 
undergoing treatment for arm lymphedema (compression garment/bandages, 
manual lymphatic drainage, or kinesiotape applications). 
Statistical analysis 
Statistical analysis was performed using SPSS 20.0 (Chicago, Illinois). Data are 
presented as numbers with percentages for categorical variables and means 
with standard deviation or medians with range for continuous variables. 
Summary statistics were obtained using Chi square tests and Fisher’s exact 
tests for categorical data and student’s t-test and Mann-Whitney U test (non 
normal distribution) for continuous variables. Univariable and multivariable 
logistic regression analyses were performed to determine the association 
between BCRL and clinical characteristics, specifically the association of BCRL 
with breast reconstruction. The odds ratio (OR) and 95% confidence interval 
(95% CI) are provided. A p-value of <0.05 was considered statistically 
significant. 
 
Results 
Patient characteristics 
130 patients underwent mastectomy with (55%) and without (45%) breast 
reconstruction. These women were examined and interviewed after a mean 
follow-up of 42.86 (SD 19.92) months after mastectomy. The patients in the 
breast reconstruction group were significantly younger (p<0.001) and had fewer 
lymph nodes removed (p=0.04) than their counterparts in the mastectomy only 
group. The majority of the reconstructive surgeries were done immediately  
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Table 1. Characteristics of the women with and without BCRL 
Variables                  No BCRL (n=87)     BCRL (n= 43)            p-value 
Age at mastectomy, mean (SD), years 53.92 (10.36) 54.61 (11.37) 0.73 
Age at FU, mean (SD), years 57.65 (10.11) 57.82 (11.12) 0.93 
BMI (kg/m
2
) at FU, mean (SD) 26.17 (5.36) 27.22 (4.94) 0.07 
Time since mastectomy, mean (SD), 
months 
44.78 (19.21) 37.75 (18.27) 0.08 
Time since reconstruction, mean (SD), 
months 
35.68 (17.03) 31.45 (16.67) 0.44 
Lymph nodes removed, mean (SD) 15.80 (4.62) 17.60 (5.88) 0.06 
Positive lymph nodes removed, median 
[range]  
2 [0 – 18] 2 [0 – 20]  0.93 
Side of surgery is dominant, no (%) 45 (51) 22 (51) 0.95 
Neo-adjuvant chemotherapy, no (%) 19 (22) 11 (26) 0.63 
Adjuvant Therapy, no (%)    
     Chemotherapy 50 (57) 27 (64) 0.42 
     Trastuzumab 21 (24)   7 (17) 0.35 
     Radiation therapy 41 (46) 24 (56) 0.35 
     Hormone therapy 63 (72) 33 (77) 0.60 
Seroma, no (%) 23 (26) 16 (38) 0.21 
History of erysipelas in arm, no (%)   4 (5)   9 (21) 0.01 
History of injury in arm, no (%)   1 (1)   6 (14) 0.005 
Difference in arm volume, mean (SD), ml 40.58 (115.25) 221.18 (220.30) <0.001 
Breast reconstruction, no (%)    0.001 
     Autologous 23 (26)   6 (14)  
     TE /implant 22 (25)   4 (10)  
     LDM flap & implant    3 (3)   1 (2)  
Abbreviations: SD; standard deviation, no; number, FU; follow-up, BMI; body mass index, SLNB; 
sentinel lymph node biopsy, ALND; axillary lymph node dissection, TE; tissue expander, LDM; 
latissimus dorsi myocutaneous.  
 
 
following mastectomy in the same surgical session (54%). Of the total number 
of breast reconstructions performed, 29 were autologous-based, 26 were with a 
tissue expander- or an implant and 4 were with a combination of a latissimus 
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dorsi myocutaneous flap and an implant. The deep inferior epigastric perforator 
(DIEP) flap was the most performed autologous-based breast reconstruction 
(83%). 
Prevalence of BCRL 
A total of 56 (43%) women had complaints of subjective arm swelling. The 
prevalence was 49% (n=35) in the mastectomy only group and 36% (n=21) in 
the reconstruction group (p=0.12). As for an inter-limb volume difference of 
>200ml, this concerned 28 (21%) women, of which 30% (n=21) were in de 
mastectomy only group and 12% (n=7) in the reconstruction group (p=0.01). 
Furthermore, 36 (28%) women were undergoing treatment for arm 
lymphedema, 38% (n=27) in the mastectomy only group and 15% (n=9) in the 
reconstruction group (p=0.004). Ultimately, 43 (33%) patients met the criteria 
for BCRL at the time of follow up (Table 1). When looking at the BCRL 
prevalence of each group individually, a rate of 45% (n=32) was observed in the 
mastectomy only group and 19% (n=11) in the reconstruction group (p=0.001).  
Predictors of BCRL 
Table 2 presents univariable & multivariable logistic regression analyses of 
factors associated with the development of BCRL. On univariable logistic 
regression analyses, patients with a history of injury of the affected arm since 
mastectomy (OR= 14.50) or a history of an episode of erysipelas (OR= 5.73) in 
the affected arm since mastectomy were associated with BCRL. A multivariable 
logistic regression analysis was performed using the following three variables: 
history of erysipelas, history of injury, and breast reconstruction (Table 3). In 
this model, breast reconstruction was associated with a significantly lower risk 
of having BCRL (OR= 0.30; 95% CI 0.13 – 0.72). Furthermore, history of injury 
and history of erysipelas in the affected arm were significantly associated with 
an increased likelihood of having BCRL, with an OR of 12.55 (95% CI 1.32 – 
112.09), 5.07 (95% CI 1.36 – 18.83), respectively. A distinction could not be 
made between the different types of reconstructive breast surgeries due to the 
small number of patients in these subgroups. 
 
 
 
 
Table 2. Univariable & multivariable logistic regression analyses of factors associated 
with the development of BCRL 
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Prognostic factor OR 95% CI p-value OR 95% CI p-value 
Age  1.01  0.97 – 1.04 0.61 --- --- ---  
LN’s removed 1.07 0.99 – 1.15 0.07 --- --- -- 
Erysipelas (yes/no) 5.73 1.65 – 19.88 0.006 5.07 1.36 – 18.83 0.015 
Injury (yes/no) 14.50 1.68 – 124.77 0.015 12.55 1.32 – 112.09 0.028 
BR (yes/no) 0.25 0.11 – 0.57 <0.001 0.30 0.13 – 0.72 0.007 
 
Abbreviations: OR; odds ratio, 95% CI; 95% confidence interval, LN’s; lymph nodes, BR; breast 
reconstruction 
 
 
 
Discussion 
In this study, breast cancer survivors who underwent mastectomy with ALND 
followed by breast reconstruction had a significantly lower risk of developing 
BCRL compared to their counterparts who only underwent mastectomy with 
ALND. This finding is in line with the current body of evidence; reports from 
comparative studies show a possible protective effect of breast reconstruction 
on the risk of developing BCRL.
14 – 16
 Moreover, when looking at the incidence 
of BCRL in a cohort of women after delayed autologous reconstruction
17
 and 
after a combination of immediate autologous or implant-based 
reconstructions
18
, rates were found to be low.  We were not able to determine if 
the difference amongst the reconstructive methods influenced the prevalence of 
BCRL in our population, due to the small number of patients in each group and 
the low prevalence of BCRL in the study cohort. Although the method of 
reconstruction is not likely to have an influence on the development of BCRL, 
choosing the internal mammary vessels as recipient instead of the axillary 
vessels in free autologous reconstructions seems to be associated with a lower 
BCRL risk.
18
 All free flap reconstructions in our study were anastomosed to 
internal mammary vessels or their perforator vessels.    
Besides the patients undergoing compression therapy for BCRL, we diagnosed 
BCRL using subjective and objective measurements. Volumetric limb analysis 
by means of water displacement is currently considered to be “the gold 
standard” for diagnosing BCRL.
19
 However, we included patient perception of 
arm swelling as a criterion for defining BCRL with the intention to reduce false 
positive diagnoses and ensure that the measured inter-limb volume difference 
was due to lymphedema and not pre-existing non pathologic volume 
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differences (muscle, fat).
20, 21
 We also identified women reporting subjective 
arm swelling without a limb volume increase, which could be the result of 
sensory changes interpreted by the patient as a feeling of swelling. In saying 
this, the method of limb measurement strongly influences outcome (BCRL).
20
 In 
a previous publication we demonstrated the need for uniformity of the 
diagnostic criteria for BCRL, as using different measuring methods resulted in 
variable prevalence rates in a single cohort.
20 
Many authors do not elaborate on 
their criteria used to define BCRL. Of the five studies published on the 
association of BCRL with breast reconstruction, only Avraham et al
16
 provided a 
clear definition for their criteria for BCRL, while the other four authors
14, 15, 17, 18 
disregarded this important factor.          
In the literature several physiological mechanisms have been mentioned 
through which breast reconstruction might protect against the development of 
BCRL. Firstly, it is suggested that an autologous flap reconstruction serves as a 
lymphatic bridge
22 
or even constitutes regenerative properties due to the newly 
transposed lymphatic tissue accompanied in the flap.
23
 Moreover, in the case of 
an implant-based reconstruction, Blanchard et al propose a hypothesis of a 
“vacuum pump” effect for the lymphatic system.
24
 We assume that the 
increased circulation in the highly vascularized capsule, which forms around the 
implant, induces a concomitant increase in lymphatic flow. Future investigations 
with flow imaging lymphoscintigraphy are needed to confirm this hypothesis.  
Some authors have established the positive impact of autologous breast 
reconstruction on patients with already existing BCRL, reporting a decrease in 
limb volume post-operatively.
24 – 26
 In addition, simultaneous breast and 
lymphatic reconstruction as a treatment for upper-limb BCRL showed promising 
short-term results.
27
 If confirmed in further studies these findings would 
significantly influence the current management of post-mastectomy patients. 
        
The strength of our study is the use of a combination of clearly defined 
subjective and objective measurements to define BCRL and the fact that 
assessment was done by the same dedicated investigators for all patients in 
this study cohort, thus reducing the risk of inter-observer variability of the 
measured outcomes. In addition, by describing the prevalence instead of the 
incidence of BCRL at 3.5 years after mastectomy we believe to have filtered out 
the cases with acute lymphedema that develop in the direct post-operative 
stage but disappear, thus only identifying the chronic BCRL cases during 
follow-up. Even though BCRL can develop any time after breast surgery, with a 
follow-up of almost 4 years after mastectomy we expect to have included a 
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representative group.
28
 On the other hand, the lack of a preoperative 
assessment of the limb volume might be considered as a limitation of our study. 
Another potential weakness is its non-randomized design and thus the risk of 
confounding by indication. A statistically significant difference in the mean age 
and the number of lymph nodes removed was found between the mastectomy 
and reconstruction group. As for age, the literature shows inconsistent results 
about the relationship between this variable and the risk of BCRL. Most studies 
report no association between age and BCRL, while some found a decreased 
risk among older patients.
31
 These reports make younger age in the 
reconstruction group an unlikely explanation for our observation of a lower 
prevalence of BCRL in this group. When looking in the literature reporting on 
the association of the number of lymph nodes removed and BCRL, a 
decreasing trend in the odds for BCRL is seen as the difference in removed 
lymph nodes between the compared groups becomes smaller. Ahmed et al. 
report a 3.52 higher odds of having BCRL in women with >20 lymph nodes 
removed versus those with no lymph nodes removed.
29
 Meeske et al. describe 
a 2.16 higher odds of having BCRL in women with ≥ 10 lymph nodes removed 
versus those with no lymph nodes removed.
30
 The most recent study, by 
Dominick et al., reports a 1.65 higher odds of BCRL in women with ≥16 lymph 
nodes removed as compared to those with ≤ 10 lymph nodes removed.
31
 The 
mean number of lymph nodes removed in our study was only 1.8 nodes higher 
in the mastectomy only group than in the reconstruction group. Taking the 
above evidence into account, it is unlikely that such a small difference would 
lead to a clinically relevant increase of the BCRL risk in the mastectomy group. 
Unfortunately, it is most unlikely that a randomized study will ever be performed 
with the aim to determine the effect of reconstructive breast surgery on the 
BCRL risk. Being aware of that, the best evidence we can acquire is evidence 
from studies like ours in which sufficient measures have been taken to rule out 
the impact of potential confounders.  
Conclusion  
In summary, BCRL was less frequently observed in patients undergoing breast 
reconstruction after mastectomy. Further studies are needed to confirm the 
association of breast reconstruction with BCRL. This information is of interest 
for the surgical decision making process.   
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Abstract 
 
Aim: To evaluate the quality of life (QOL) of breast cancer survivors who 
have undergone breast reconstruction and have breast cancer related 
lymphedema (BCRL).  
 
Methods: Patients with a unilateral mastectomy with or without breast 
reconstruction were evaluated for BCRL and their QOL. Patients were 
divided into a non-BCRL and a BCRL group. Patients with subjective 
complaints of arm swelling and/or an inter-limb volume difference of 
>200ml, or undergoing treatment for arm lymphedema were defined as 
having BCRL. QOL was assessed using cancer-specific (EORTC QLQ-
C30 and EORTC QLQ-B23) and disease specific (Lymph-ICF) 
questionnaires.  
 
Results: 253 patients with a mean follow-up time of 51.7 (±18.5) months since 
mastectomy completed the QOL questionnaires. Of these patients, 116 (46%) 
underwent mastectomy alone and 137 (54%) had additional breast 
reconstruction. A comparison of the QOL scores of 180 patients in the non-
BCRL group showed a significantly better physical function (p=0.004) for 
patients with reconstructive surgery compared to mastectomy patients. In the 
73 patients with BCRL, a comparison of the QOL scores showed no significant 
differences between patients with mastectomy and reconstructive surgery. 
After adjusting for potential confounders, multivariate analysis showed a 
significant impact of BCRL on physical function (β= -7.46; p=0.009), role 
function (β= -15.75; p=0.003), cognitive function (β= -11.56; p=0.005), body 
vision (β= -11.62; p=0.007), arm symptoms (β= 20.78; p=0.000) and all 
domains of the Lymf-ICF questionnaire. 
 
Conclusions: This study implies that BCRL has a negative effect on the 
QOL of breast cancer survivors, negating the positive effects on QOL 
reconstructive breast surgery has.  
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Introduction 
Survival rates of breast cancer have increased over the past years.
1
 With a 
long-term survival rate of >80%, a growing number of women are living 
with the side effects of breast cancer treatment.
2
 It is therefore logical that 
the quality of life (QOL) has become an important outcome measure in 
many breast cancer studies.      
One of the most debilitating side effects of breast cancer treatment is 
upper-limb lymphedema, also known as breast cancer related 
lymphedema (BCRL). The lymphatic system of the upper-limb can be 
damaged due to axillary surgery, radiation and/or chemotherapy, resulting 
in stasis of lymph fluid and an increased limb volume. BCRL can develop 
directly after surgery or, in most cases, in the first four years after breast 
cancer treatment.
5 
Patients may develop symptoms of heaviness, 
tightness, pain sensations, loss of normal upper-limb function and range of 
motion.
6
 Breast cancer survivors with BCRL have a significantly lower QOL 
than patients without arm morbidity.
5-11
     
There is evidence that breast reconstruction has a positive effect on the 
QOL of breast cancer patients.
12
 However, is this positive effect also 
present in patients with BCRL? As of yet, no attention has been given to 
the assessment of the QOL in patients with BCRL who have also 
undergone breast reconstruction. With this study we hope to obtain a 
better understanding of the impact of BCRL on the QOL of breast cancer 
survivors with reconstructive breast surgery. Therefore, our aim is to 
explore the QOL in patients with or without BCRL who have undergone 
mastectomy alone or mastectomy followed by reconstructive breast 
surgery.  
Methods 
Patients 
This study is part of a secondary analysis of a multicenter study analyzing the 
influence of breast reconstruction on the development of BCRL.
13
  A total of 
283 patients, who underwent a unilateral mastectomy with or without a breast 
reconstruction between January 2006 and December 2010, were analyzed for 
the development of BCRL. Information on the surgical procedures (oncological 
and reconstructive), tumor characteristics and adjuvant medical treatment were 
obtained from hospital medical records. The Medical Research Ethics 
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Committee of the Maastricht University Hospital approved this secondary 
analysis.     
A total of 274 (97%) patients gave written approval to be contacted for a 
secondary study. All patients were asked to participate in a standardized QOL 
interview. 21 patients were excluded because they could not be reached, had 
deceased, or refused to participate, resulting in a study population of 253 
patients. In order to investigate the QOL in patients with BCRL, patients were 
divided into two groups: a non-BCRL group and a BCRL group.    
The BCRL group consisted of patients with subjective complaints of arm 
swelling and/or an inter-limb volume difference of >200ml, or undergoing 
treatment for arm lymphedema. Subjective complaints of arm swelling were 
positive when patients said to have experienced swelling in the upper-limb on 
the breast cancer treated side in the past year. The inter-limb volume 
difference was measured using the water displacement method, which 
currently is considered as the gold standard.
14 
 
Quality of life questionnaires  
Standardized interviews were conducted by telephone by one researcher 
(BB). Patients were surveyed using three validated QOL questionnaires: the 
Dutch version of the European Organization of Research and Treatment for 
Cancer (EORTC) QLQ-C30 version 3.0 with the EORTC QLQ-BR23 breast 
cancer supplementary module
15 – 17 
and The Lymphedema Functioning, 
Disability and Health questionnaire (Lymph-ICF).
18
 Permission to use the 
questionnaires for research purposes was granted. 
EORTC QLQ-C30  
The EORTC QLQ-C30 measures the QOL of cancer patients. As indicated 
by the EORTC answers were converted in to a 0-100 score on five 
functional scales: physical, role, emotional, cognitive and social functioning, 
a global health status scale and several symptom scales including: fatigue, 
nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, 
diarrhea and financial difficulties. Due to the mean follow-up time of this 
study (51.7±18.5 months since mastectomy), the symptoms scales were 
not included in the analyses as they mostly relate to systemic therapy and 
their side effects. A lower score on the functional scales and the global 
health status scale correlates with a lower QOL.  
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EORTC QLQ-BR23 
The breast cancer specific EORTC QLQ-BR23 consists of 23-items, divided 
into four functional scales – body image, sexual functioning, sexual 
pleasure and future perspective – and four symptom scales – arm 
symptoms, breast symptoms, systemic therapy side effects and upset by 
hair loss. Scoring is identical to the EORTC QLQ C-30 questionnaire. 
Systemic therapy side effects and upset by hair loss were not included in 
the analyses due to the mean follow-up time. The sexual functioning and 
the sexual pleasure domain were also excluded from analyses, as almost 
half of the population (44%) chose not to fill in the question or indicated not 
to be sexually active. 
Lymph-ICF 
The Lymphedema Functioning, Disability and Health questionnaire (Lymph-
ICF) is a condition specific instrument, consisting of seven questions 
related to arm symptoms and twenty-two questions pertaining to 
impairments in function of activity of daily living (ADL). Per subscale 
patients were asked to score their level of complaints, on a scale of 0 to 10 
centimeters, where 0 was comparable to no complaints and 10 to a lot of 
complaints to that specific question. Answers were converted in to a 0-100 
score, where 1 cm corresponds with 10 points on the 0-100 score.  
QOL measurements  
The QOL was assessed in all patients using the three questionnaires. We 
compared the QOL scores at four different levels. The first comparison was 
made to assess the impact of BCRL on QOL in this cohort; the QOL scores 
in the non-BCRL group were compared to the QOL scores in the BCRL 
group. Furthermore, in order to obtain an understanding of the impact of 
BCRL on the QOL in breast cancer survivors who have undergone breast 
reconstruction, the following three comparisons were made: the QOL 
scores of reconstructive patients with mastectomy patients in the non-BCRL 
group, the QOL scores of reconstructive patients with mastectomy patients 
in the BCRL group and lastly, the QOL scores of reconstructive patients in 
the non-BCRL group with reconstructive patients in the BCRL group.  
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Statistics 
SPSS for Windows 20.0 (SPSS Inc. Chicago, Illinois) was used for 
statistical analysis. For describing patient and clinical characteristics, 
descriptive statistics were used. Mean and standard deviation were 
reported in case of continuous variables, using the independent-samples t-
test. Non-normal distributions were reported as median and ranges, the 
Mann-Whitney-Wilcoxon test was used for testing significance. Categorical 
variables were reported as number and percentages, for testing 
significance the chi-square test was used. Multiple linear regression 
analysis was used to adjust for potential confounders in the group of 
patients with reconstructive surgery, using a model containing each QOL 
domain as a separate outcome. The following confounders were used in 
the model: total number of lymph nodes removed during sentinel node 
biopsy and/ or full axillary clearance, BCRL, radiation treatment and 
chemotherapy. A P-value of <0.05 was considered statistically significant 
for all tests. 
 
Results 
Patient characteristics 
Of the 253 patients, 116 (46%) underwent mastectomy alone and 137 
(54%) had additional breast reconstruction. Patients with breast 
reconstruction were significantly younger (p<0.001), had a lower BMI at 
follow-up (p=0.02) and less frequently underwent axillary lymph node 
dissection (p=0.00). Mastectomy patients had a significantly higher level of 
history of seroma (p=0.01) and trauma to the arm (p=0.03). Interviews were 
performed after a mean follow-up of 51.7 (±18.5) months post-mastectomy 
(table 1). Reconstructive surgery was performed in the same surgical 
session in 66% and secondarily in 34% of the total breast reconstructions. 
Tissue expander/implant reconstruction was done in 56%, autologous 
reconstruction in 39% and 5% of the patients had a combination of an 
implant and a latissimus dorsi flap.  
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Table 1. Patient characteristics 
Abbreviations: SD; standard deviation, no; number, mo; months, FU; follow-up, BMI; body mass 
index, SLNB; sentinel lymph node biopsy, ALND; axillary lymph node dissection, LN’s; lymph 
nodes 
Variables                                 Total                   Mastectomy       Reconstruction        p-value 
                    (n=253)                (n=116)                     (n=137) 
Age at mastectomy, mean (SD) 54.6 (10.1) 59.6 (10) 50.4 (8.1) 0.00 
Age at FU, mean (SD) 58.1 (10.2) 63.2 (10.1) 53.8 (8.0) 0.00 
BMI (kg/m
2
) at FU, mean (SD) 27.0 (5.4) 27.8 (5.8) 26.2 (4.9) 0.02 
Time since mastectomy, mean 
(SD), mo 
51.7 (18.5) 52.8 (19.7) 50.9 (17.4) 0.28 
Tumor stage, no (%)  0.16 
    pT0 – pT1 119 (48) 47 (40) 72 (54)  
    pT2 – pT3 100 (39) 54 (47) 46 (33)  
    ypT0 – ypT4 34 (13) 15 (13) 19 (13)  
Axillary surgery, no (%)    0.00 
    SNLB 131 (52) 55 (47) 75 (55)  
    SNLB/ALND 117 (46) 61 (53) 56 (41)  
LN’s removed, median [range] 5 [0 – 29] 10 [1 – 29] 3 [0 – 29] 0.02 
Positive LN’s removed, median 
[range]   
0 [0 – 20] 0 [0 – 20] 0 [0 – 13] 0.03 
BCRL (%) 75 (30) 38 (33) 35 (25)  
Dominant arm, no (%) 126 (50) 57 (49) 69 (50) 0.89 
Seroma, no (%) 68 (27) 40 (34) 28 (20) 0.01 
History of erysipelas, no (%) 17 (7) 10 (9) 7 (3) 0.26 
History of injury, no (%) 10 (4) 8 (7) 2 (1) 0.03 
Neo-adjuvant chemotherapy, no 
(%) 
31 (12) 15 (13) 16 (12) 0.75 
Adjuvant therapy, no (%)  
   Chemotherapy 115 (45) 52 (45) 63 (46) 0.90 
   Trastuzumab 38 (15) 16 (14) 22 (16) 0.63 
   Radiation therapy 62 (24) 35 (30) 27 (20) 0.05 
   Hormone therapy 139 (55) 69 (59) 70 (51) 0.16 
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Characteristics of patients with BCRL 
A total of 73 (29%) patients had subjective complaints of arm swelling 
and/or an inter-limb volume difference of >200ml or undergoing treatment 
for arm lymphedema, of which 38 (33%) were in the mastectomy group and 
35 (25%) in the reconstruction group. The patients in the breast 
reconstruction group were significantly younger (p<0.001) and had 
significantly less lymph nodes removed (p=0.05) compared to the patients 
in the mastectomy group. Reconstructive surgery was performed in the 
same surgical session in 49% and secondarily in 51% of the patients. 
Autologous reconstruction was done in 58% of the patients, 31% had a 
tissue expander/implant and 11% received a combination of an implant and 
a latissimus dorsi flap.  
Overall QOL scores: non-BCRL vs BCRL group 
Significantly lower scores were found in the BCRL group on all domains of 
the three QOL questionnaires, as compared to the non-BCRL group. 
Figures 1 – 4 provide an overview of the mean scores arranged by type of 
surgery and BCRL status. 
QOL scores in the non-BCRL group: mastectomy vs reconstruction  
Patients with breast reconstruction scored significantly higher on the 
physical functioning domain (p=0.004).  
QOL scores in the BCRL group: mastectomy vs reconstruction 
No statistically significant differences were found. 
QOL scores of reconstruction patients: non-BCRL vs BCRL group 
Patients in the BCRL group scored significantly lower on all EORTC 
domains, except for two: future perspective (p=0.10) and breast symptoms 
(p=0.15). The women in the BCRL group also reported significantly more 
complaints on all domains of the Lymf-ICF questionnaire. 
Multivariate Analysis 
We further assessed the QOL domains in the group of women who had 
undergone breast reconstruction in a multiple linear regression, taking into 
account the presence of BCRL, total number of lymph nodes removed, 
radiation treatment and use of chemotherapy. After adjustment of these 
Chapter 6  
 89 
covariates BCRL was significantly associated with a lower score on the 
following domains: physical function (β= -7.46; p=0.009), role function (β= -
15.75; p=0.003), cognitive function (β= -11.56; p=0.005) and body vision (β= -
11.62; p=0.007). Furthermore, BCRL was also associated with significantly 
higher scores on all domains of the Lymf-ICF questionnaire.  
 
Figure 1-4. Median quality of life scores per domain shown by breast reconstruction 
and BCRL status. 
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Blue bar: mastectomy patients with BCRL, Green bar: reconstruction patients with BCRL, Yellow 
bar: mastectomy patients without BCRL, Red bar: reconstruction patients without BCRL. 
 
Discussion 
In this cross-sectional study, we report on the impact of BCRL on the QOL 
of breast cancer survivors with and without breast reconstruction. We 
included women who underwent autologous-, implant- and a combination of 
implant and latissimus dorsi flap reconstruction in the same surgical 
session as the mastectomy or secondarily. Irrespective of having 
undergone breast reconstruction, our data suggests that BCRL has a 
negative effect on the QOL of breast cancer patients. This is an important 
observation, as in plastic surgery most surgical procedures are aimed at 
improving the health related quality of life. In other words, BCRL can undo 
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the positive effect on the overall well-being of breast cancer survivors that is 
achieved with breast reconstruction. 
21- 24
 However, when we compared the 
QOL outcomes of the women in the non-BCRL group, those who 
underwent breast reconstruction only scored higher on the physical domain, 
as compared to the women who only underwent a mastectomy. The 
expected benefit of breast reconstruction on the psychological- and 
emotional well-being is not seen in this group. This may be related to the 
effect of the time that had elapsed since surgery, which was circa 52 
months. A study by Metcalfe et al., in which the changes in psychosocial 
well-being of women who underwent breast reconstruction and mastectomy 
alone were monitored over a period of approximately 6 years, reported a 
significant improvement in QOL in both groups over time.
25 
 
Quality of life questionnaires 
Despite the fact that the EORTC QLQ-C30 and the EORTC QLQ-BR23 
were not specifically designed to be used among patients who have 
undergone reconstructive breast surgery, these were the most suitable 
QOL questionnaires available at the time this study was performed. These 
are valid and reliable questionnaires that can be used among breast cancer 
patients, and give good insight on the QOL of the research population.
15,16
  
Moreover, we also used the disease-specific Lymf-ICF questionnaire which 
is a reliable and valid questionnaire that is used to assess impairments in 
function, activity limitations and participation restrictions of patients with arm 
lymphedema after breast cancer surgery.
18
 Currently, there are a few 
validated patient-reported QOL questionnaires available that can be used 
among breast reconstruction patients. The QLQ-BRR26, a new validated 
EORTC module specific for breast reconstructive patients, is developed as 
a supplement to the EORTC QLQ-C30 and the EORTC QLQ-BR23. This 
model also makes it possible to make a comparison of QOL among 
different breast reconstruction techniques.
30 
Furthermore, the BREAST-Q is 
another QOL questionnaire that can be used in breast augmentation, breast 
reduction and breast reconstructive patients. The questionnaire measures 
the surgery-related QOL and is specifically designed to measure the 
satisfaction among breast augmentation, breast reduction and breast 
reconstructive patients. A disadvantage of the BREAST-Q is that the 
questionnaire was not developed to be used among mastectomy patients
31
, 
which is why it was not used in this study. The Michigan Breast 
Reconstruction Outcome Study Satisfaction (MBROS-S) questionnaire and 
the Breast-Related Symptoms Questionnaire (BRSQ) are two other QOL 
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questionnaires that can be used among breast reconstructive patients, but 
have limited validation for all breast reconstructive techniques.
32
 
Strengths and limitations 
One of the strengths of this study is the long mean follow-up time of more 
than 4 years, which excludes patients with acute lymphedema and physical 
complaints occurring directly post-operatively or related to adjuvant therapy, 
resulting in a study population of only chronic BCRL patients. Petrek et al. 
showed that in most patients the onset of BCRL will develop in the first 4 
years after treatment, probably making this study population with a mean 
follow-up of more than 4 year a representative group.
3
 The measurement of 
BCRL by using the use of the water displacement method, which is the gold 
standard for the measurement of BCRL, is another strength of this study. 
Furthermore, our study is the first to evaluate the QOL of breast cancer 
survivors after mastectomy alone and reconstructive breast surgery that 
have developed BCRL. However, several limitations of our study should 
also be mentioned. As a result of the cross-sectional design, 
measurements of baseline parameters immediately after surgery were not 
performed, making it impossible to measure the change in QOL. Shi et al 
reported the importance of a baseline measurement and showed that there 
is a significant improvement of QOL during the first years after surgery.
24
 
Secondly, not all psychological and socio-demographic influences such as 
educational level, employment status, financial difficulties were 
incorporated into this study. The health related quality of life is a multi-
dimensional entity. Disease related characteristics such as time since 
mastectomy, radiation, chemotherapy, hormone therapy and tumor stage 
are not the only important confounding factors. Lee et al. has reported on 
the relevance of socio-demographic characteristics as confounding factors 
for the QOL.
33
 
Future directions 
Due to the large impact of BCRL on the QOL of breast cancer survivors, a 
growing interest is shown for microlymphatic surgery as a potential 
treatment option for BCRL.
33,34
 In a systematic review we investigated the 
outcome of microlymphatic surgery, including lymphatic vessel transfer, 
composite tissue transfer and derivate surgery, on symptoms, limb 
circumference, limb volume and improvement of the lymphatic function.
36
 
The available literature shows positive results with regards to limb 
volume/circumference reduction. Furthermore, few complications after 
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microlymphatic surgery are reported.
35 
These findings underline the 
importance of future research to further assess the effectivity of 
microlymphatic surgery as a treatment option for BCRL.  
Conclusion 
In conclusion, this study implies that BCRL has a negative effect on the 
QOL of breast cancer survivors, potentially negating the positive effects on 
QOL reconstructive breast surgery has. It is therefore imperative for the 
quality of breast cancer survivorship that research is continued on the 
subject of curative BCRL treatment options, such a microlymphatic surgery.  
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Abstract 
Background: Upper limb lymphedema is one of the most underestimated and 
debilitating complications of breast cancer treatment. The aim of this review is 
to summarize the recent literature for evidence of the effectiveness of lymphatic 
microsurgery for the treatment of breast cancer related lymphedema (BCRL).  
 
Methods: A search was conducted for articles published from 2000 onwards. 
Only studies on secondary lymphedema after breast cancer treatment and 
those examining the effectiveness of microsurgery were included. The following 
data was extracted: surgical intervention type, population size, follow-up time, 
BCRL classification, duration of BCRL, arm volume/circumference reduction, 
lymph-flow improvement, symptom relief, post-operative conservative therapy 
discontinuation and complications.  
 
Results: No randomized clinical trials or comparative studies were available; 
ten case-series met inclusion criteria. Three surgical techniques were 
described: (composite) tissue transfer (n=4), lymphatic vessel transfer (n=2) 
and derivative microlymphatic surgery (n=4). Limb volume/circumference 
reduction varied from 2%- 50% over a follow-up time ranging from 1 to 132 
months. Post-operative discontinuation rates of conservative therapy were only 
reported after composite tissue transfer, ranging from 33 to 100% after 3 to 24 
months. Little to no complications were observed in all surgical techniques. 
Clear selection criteria for lymphatic surgery and lymphatic flow assessment 
were absent in most studies.  
 
Conclusion: We identified the important methodological shortcomings of the 
available literature. Evidence acquired through comparative studies with 
uniform patient selection is lacking. Consistent positive findings with regards to 
volume/ circumference reduction and limited complications are reasons to 
further explore these techniques in methodologically superior studies. 
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Introduction 
Upper limb lymphedema is one of the most underestimated and debilitating 
complications of breast cancer treatment. Hitherto, lymphedema treatment 
options have mainly been based on the lifelong application of a combination of 
conservative techniques, such as compression garments/bandages and manual 
lymph drainage.
1-3 
Conservative therapy is initially aimed at alleviating 
symptoms without curative intent; with such treatment, some patients may 
achieve sufficient limb volume reduction and symptom relief. In cases of 
inadequate disease management, lymphedema may progress: arm-swelling 
transforming from a predominantly fluid encompassing entity to fibrosis and 
fat.
4, 5
 Lymphedema in its late chronic phase is irreversible and accompanied by 
more symptoms and physical impairments, consequently compromising the 
quality of survivorship.
6-10  
An alternative treatment option could be beneficial for 
patients that aren’t responsive to standard conservative therapy. Lymphatic 
microsurgery could be such a treatment option, if treatment would be applied 
before lymphedema reaches its chronic, irreversible phase.  
Derivative (super) microlymphatic surgery 
Microlymphatic repair for lymph edematous limbs emerged with the 
development of reconstructive microsurgery in the late 1960’s. The very first 
experimental studies reported, were in obstructive canine models. In these 
studies communications were created between the lymphatic and venous 
systems to divert static lymph fluid away from the obstruction site in a technique 
called lymphatic venous anastomoses.
11
The canine studies reported low and 
inconsistent patency rates as the result of this intervention, triggering the further 
development of the derivative microlymphatic technique. Refinements were 
made in order to reduce the chances of venous back flow and consequently 
bypass stenosis. However, limitations in the available microsurgical technology 
hampered the long-term establishment of viable anastomoses, as the pressure 
gradient between the lymphatic- and venous systems were still too high. Until 
the beginning of this millennium there was little progression in lymphatic 
surgical techniques. In the contemporary clinical field of microvascular surgery 
anastomoses with vessels as small as 0.3mm in diameter are possible, this also 
known as “super microsurgery”. Because of these technical refinements it is 
now possible to create multiple bypasses between lymphatic vessels (ranging 
from 0.3mm- 0.5mm) and venular vessels (0.5mm) found in the subdermal 
plane of a lymph edematous limb. Anastomosing smaller vessels of the two 
vascular systems is hypothesized to ensure better bypass patency due to the 
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minor intra-vascular pressure differences.
12
 Over the years evidence has been 
reported of lymphatic repair being effective in patients with secondary 
lymphedema of both the upper and lower extremities using lymphatic venular 
anastomoses.
13-15
 
Tissue Transfer 
Another technique to improve lymphatic drainage is the vascularized lymph 
node transfer with or without simultaneous free flap reconstruction.
16
 
Experimental studies on lymph node transplantation in small animal studies 
have reported promising results of lymphatic function restoration, and with that, 
the facilitation of lymphedema resolution.
17,18
  Moreover, an alternative 
approach is achieved through the interposition of autologous tissue (i.e. lymph 
vessel), in which an attempt is made to restore flow within a damaged lymphatic 
system by bypassing the site of blockage. The transplanted lymph vessel(s) 
can function as a bridge connecting the afferent and efferent lymphatic vessels 
from the obstruction site.
19 
 
The recent movement towards the incorporation of evidence-based medicine 
into plastic surgery
20
 has stressed the importance of good quality research as 
the core of the clinical decision making process. The primary aim of this 
systematic review is to summarize the recent literature for evidence of the 
effectiveness of lymphatic microsurgery for the treatment of breast cancer 
related lymphedema (BCRL). Specifically, the effect of surgery on upper-limb 
volume/circumference reduction, symptom relief, lymph flow improvement and 
the discontinuation of compression therapy post-operatively will be evaluated. 
 
Methods 
Literature search 
An electronic literature search was conducted in MEDLINE and PubMed for 
literature published from January 2000 onwards. Three independent 
investigators (TLP, NH, CI) performed the search. The following search terms 
were used: lymphedema, lymphoedema, microsurgery, surgical treatment, 
breast cancer, lymph node transfer, lymphovenous anastomoses, 
lymphaticovenular anastomoses and lymph vessel transplantation. The search 
was limited to English, Dutch, German and French literature, while we also 
hand-searched reference lists of the relevant articles found. Abstracts were 
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scanned for relevance. Only the studies providing data of patients with 
secondary lymphedema after breast cancer treatment and those examining the 
effectiveness of microsurgical intervention were eligible for inclusion. Data from 
studies on primary lymphedema, lower extremity lymphedema and mixed 
groups of lower and upper extremity lymphedema were excluded. All articles 
were evaluated for duplicate reporting on the same patient population and if so 
removed.   
Data extraction  
The following data were extracted if available: surgical intervention type (lymph 
node transplantation, lymph vessel transplantation or derivative lymphatic 
surgery), size of the patient population, mean follow-up time, BCRL 
classification and stage, mean duration of BCRL before surgery, arm volume or 
circumference reduction, lymph flow improvement as quantified by 
lymphoscintigraphy, symptom relief (self-perceived pain, heaviness and 
erysipelas), discontinuation of post-operative conservative therapy 
(compression garments/bandages or manual lymphatic drainage) and 
complications (donor or recipient site morbidity).  
Quality assessment 
A detailed methodological quality assessment was conducted independently by 
three investigators (TLP, CI, NH). The case series were assessed using an 8-
question checklist from The American Society of Plastic Surgeons (ASPS) for 
therapeutic studies. 
21
 Each affirmative answer was a point. Thus, a total score 
of 8 was the maximum to be assigned per case series. The quality scores were 
compared and disagreements resolved by consensus.    
Data analysis 
The median and range of the methodological quality rating of all the studies 
combined, as well as the studies per surgical technique are provided. We 
compared the median quality ratings using the Mann-Whitney U test. A p-value 
< 0.05 was considered significant. Data-analysis was conducted using SPSS 
for Mac 17.0 (SPSS Inc. Chicago, Illinois). 
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Results 
There were no randomized clinical trials or comparative studies available, thus 
we were limited to the inclusion of case-series. A total of 19 case-series were 
identified. Nine
22-30 
were excluded as they described either lymphedema of only 
the lower extremity
22-25
, a mix of lower and upper extremity lymphedema
26-29 
or 
a mix of primary and secondary upper extremity lymphedema.
30
 The remaining 
10 studies were included for assessment (Table 1). In these studies, three 
types of micro lymphatic surgery were described: composite tissue transfer, 
lymphatic vessel transfer and derivative surgery. The number of patients per 
case- series was small ranging from 6 - 24 women. However, one study 
reported evidence on 127 women.
35
 Follow-up time varied amongst the studies, 
ranging from 5 to 72 months in articles evaluating derivative lymphatic surgery 
and 6 to 132 months in that of (composite) tissue transfer. Different measures 
were used to assess treatment outcome. These included reduction of limb 
volume
35-39
, circumference
31, 33, 34, 37, 40 
or symptomatology
31, 32, 38-40
 and 
improvement of lymphatic function quantified by lymphoscintigraphy.
31, 33, 34, 36, 
38-40
  
 
Quality assessment 
The median methodological quality rating of the 10 studies was 4.5 [range 2-5] 
(Table 1). The studies on (composite) tissue transfer had a higher median 
quality score compared to that of derivative techniques, respectively 5 [2-5] VS 
4 [range 3-5]. However, this difference was not statistically significant p=0.567.  
Microsurgical techniques 
We were unable to pool the results of the included studies due to a few 
restricting factors. Firstly, the outcomes of interest were reported in a variable 
manner in much of the studies. Secondly, the patient populations of the 
selected studies were of heterogeneous nature. We have therefore presented a 
schematic overview of the important data.   
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Table 1. Methodological quality assessment of the case series reporting on lymphatic microsurgery for the treatment of BCRL. 
 
Ref Appropriate 
selection 
Consecutive 
cases 
Confounders 
addressed 
Intervention 
performed 
similarly 
Procedures 
performed by 1 
surgeon 
Valid & 
defined 
criteria for  
FU time 
sufficient to 
detect 
outcome 
No conflicts 
of interest  
Total 
score 
31 - + + - ? +  + + 5 
32 + ? + + ? -  + +  5 
33 + ? + - + +  + ?  5 
34 + ? + + ? + + ?  5 
35 - ? - + ? -  + ?  2 
36 - ? - + ? +  + ?  3 
37 + ? - + ? - + +  4 
38 + ? + + ? - + +  4 
39 + ? + + + +  + ?  5 
40 - ? + + ? -  + ?  3 
Abbreviations: Ref; reference, BCRL; breast cancer related lymphedema, FU; follow-up.
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1. (Composite) tissue transfer 
A total of four retrospective case series (n=52) on composite tissue transfer for 
the treatment of BCRL were identified (Table 2.). Three (n=39) described a 
similar operative technique: lymph nodes harvested at the inguinal site with the 
vascular structures and fat surrounding the superficial circumflex iliac vessels 
set in the axilla of the affected limb using the thoracodorsal vessels as recipient 
vessels.
32-34
 Of these three, Saaristo et al modified the technique by combining 
it with a DIEP/msTRAM free flap for simultaneous breast reconstruction. The 
technique described by Lin et al. differed from the other three in that the 
recipient site was the dorsal wrist of the affected arm instead of the axilla. 
Circumference reduction rate was provided by one study
31
, stating an average 
reduction of 51% at 4.7 years follow-up. As for symptom improvement, Becker 
et al. reported a reduction of pain in all 6 patients direct post-operatively and Lin 
et al. a reduction of the incidence of cellulitis in 11 of the 13 patients. Of the 
studies providing quantitative lymph flow assessment improvement was 
reported in all three.
31,33, 34
 Three studies reported the discontinuation rate of 
post-operative compression therapy, ranging from 33-100% 3 months to 2 
years after surgery.
32-34
 No donor site morbidity was reported. Two studies 
(n=139) were identified reporting on lymph vessel transplantation for the 
treatment of BCRL. The largest series (n=127), a retrospective assessment by 
Baumeister et al. reported an average volume reduction of 22% at a follow-up 
of 31 months.
35
  The rate of post-operative discontinuation of compression 
therapy was not addressed. As for post-operative complications, one case of 
donor site edema was reported. 
2. Derivative (super) microsurgical techniques 
A total of four prospective case-series (n= 47), evaluating derivative (super) 
microsurgery for the treatment of BCRL, met the inclusion criteria (Table 3). 
Three of the four studies reported a volume or circumference decrease greater 
than 30% at a follow-up time ranging from 5 to 72 months.
37, 38, 40
 Results were 
less favorable in a study by Damstra et al, reporting a limb volume reduction of 
2% with accompanying unchanged lymphatic flow, 12 months post-
operatively.
39
 Three of the four studies showed improvement of symptomatic 
complaints post-operatively.
38-40
 Although only addressed by two studies, no 
post-operative complications were reported.
38,40
 Post-operative conservative 
therapy in the form of compression therapy and/or bandaging was continued 
indefinitely in all case-series. 
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Discussion 
In this review we summarized the available literature on lymphatic microsurgery 
for the treatment of BCRL. We were primarily interested in the efficacy of 
derivative lymphatic surgery and (composite) tissue transfer on upper-limb 
volume or circumference reduction, relief of symptoms related to BCRL, 
lymphatic function and the discontinuation of conservative therapy post-
operatively. Data could only be acquired through a mix of pro- and retrospective 
case series, as randomized or comparative studies were not available. This 
resulted in level IV evidence. With respect to the methodological quality, the 
studies on composite tissue transfer rated best when compared to that of lymph 
vessel transfer and derivative surgery (Table 1). Two criteria were most often 
associated with a low methodological rating. The first is incomplete information 
on the patient selection procedure for surgery. As differentiating between early 
non-fibrotic lymphedema and chronic lymphedema is an important outcome-
determining factor recording of these lymphedema stages when selecting study 
patients is essential. Secondly, the post-surgical outcome assessment should 
not only include limb volume or circumference measurements, but should also 
be complemented with monitoring of lymphatic flow. Unfortunately, it was not 
possible to pool the results of the different studies included in this review, due 
to incomplete data documentation, but most importantly because of the large 
difference between the studies with respect to the criteria used for selecting 
patients for surgery. For example, only four studies stratified patients into 
lymphedema clinical stages before ensuing surgery, while the others did not 
take the pathophysiological nature of lymphedema into account, resulting in a 
heterogeneous patient population.      
 
Primary outcomes 
 
All but one study
39
 noted consistent reduction of upper-limb volume or 
circumference reduction from surgical intervention through derivative lymphatic 
surgery
37,38, 40
, lymph node transplantation
31-34 
or lymphatic vessel transfer. 
35,36
 
Damstra et al., reporting on results after lymphatic venous anastomosis, 
measured a disappointing mean volume difference of 2% after one year. There 
are, however, two aspects in the methodology of this study that might have 
affected the outcome. Firstly, a surgical procedure according to Degni-Cordeiro 
was applied. This is a rather outdated technique originating from the early 
1980’s
41
, a period in which derivative lymphatic surgery had proven low bypass 
patency due to the intravascular pressure gradient. Secondly, the selection 
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criteria for the group of patients that would undergo derivative lymphatic surgery 
have affected the outcome of this study. It is stated by the authors that 
complete limb volume reduction was achieved in nearly half of the patient 
population when circumferential suction-assisted lipectomy was performed after 
the initial LVA operation. This suggests a chronic lymphedema stage. The 
natural progression of lymphedema sees to the change of limb swelling 
composition, from an at first predominantly fluid containing entity to the addition 
of fibrosis, fat and protein. So, even if the static lymph fluid is relieved, swelling 
still remains in the form of excess fat and fibrosis.
42, 43
 Furthermore, chronic 
lymphedema also suggests a prolonged hypertensive state within the lymphatic 
system. This phenomenon causes irreversible damage to the lymph vessels i.e. 
degeneration of smooth muscle cells
44, 45
, rendering the lymph vessels 
incapable of lymph fluid propulsion. Therefore failure is inevitable in the 
attempts of producing patent lymphatic venous bypasses. 
 
Aside from limb volume or circumference reduction, surgery effectiveness can 
be determined by lymphatic function. Lymphoscintigraphy can visualize 
lymphatic flow, providing qualitative information on lymph transport in the 
affected limb. Only half the studies
31, 33, 34, 36, 39 
assessed in this review 
evaluated the effect of lymphatic microsurgery on the lymphatic function. This is 
a major methodological flaw, as the ultimate aim of every lymphatic surgery 
should be to repair the function of the damaged lymphatic system. Moreover, in 
derivative surgery it is important to monitor lymphatic-venular bypass patency. 
Until recently there were no means of doing so. The use of indocyanine green 
fluorescence lymphangiography appears promising in this respect.
46, 47
 
  
The effect of surgery on symptom relief was not a main focus for many of the 
studies in this review. A specific decrease in neuropathic pain and in cellulitis 
rates was reported in two small populations after lymph node transplantation.
31, 
32
 As for the effect of derivative lymphatic surgery, a subjective relief of 
symptoms was noted in 50-100% of the patients in three studies.
38-40
 
The discontinuation of post-operative conservative therapy was realized, 
although in variable rates, three to 24 months after surgery in the three studies 
evaluating inguinal lymph node transfer to the axilla of the lymph edematous 
arm.
32-34
 As reported
31, 33
, the results were better when the duration of 
lymphedema was the shortest before lymph node transfer suggesting that this 
surgery cannot only be used as an alternative treatment for conservative 
therapy-resistant BCRL, but also as a curative up-front approach for 
lymphedema.  
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 Table 2. Summary of studies on (composite) tissue transfer and derivative (super) micro lymphatic surgery for the treatment of BCRL 
 
Ref Intervention Post-operative 
conservative 
treatment 
n FU in 
mo 
BCRL classification 
& stage 
Duration 
of BCRL  
Results Complications 
31 IFP & nodes 
set in wrist  
Not mentioned 13 56       
[6-96] 
- 2.8 years    
[4-84 mo] 
C: 12/13 had reduction, 
mean of 51% [0-71%]. 
L: in all flow improvement.  
S: 11/13 had decrease 
cellulitis incidence 
Wound infection    
(n=1), venous 
congestion 
(n=1), no donor 
site morbidity 
32 IFP & nodes 
set in axilla  
No CG, MLD 
discontinued after 
3 mo 
6 21       
[13-38] 
No specification on 
staging type: I (n=4), II 
(n=2). 
- C/V: lymphedema 
resolved in 5/6 pts.  
S: 100% reduction in pain 
scale. 
No donor or 
recipient site 
morbidity  
33 IFP & nodes 
set in axilla, 
2
nd
 procedure 
(n=7) IFP set 
in elbow 
No CG, 62.5% 
stopped MLD after 
12 mo 
24 100      
[60- 132] 
- I (n=6) early edema, 
<2 infectious 
episodes, <30% 
difference.                             
- II (n=18) edema > 1 
year, >2 infectious 
episodes, difference 
30-50% 
- ≥ 1 year 
average of 
5.6 years 
(n=18)           
- <1 year, 
average 5 
months 
(n=6) 
C: 6 >50% reduction, 6< 
50% reduction, 10 
returned to normal, 2 
unchanged.  
L: 5/16 flow improvement. 
 
Lymphorrhea 
(n=8) 
34 DIEP/msTRA
M & IFP & 
nodes set in 
axilla after 
WLSE  
33% discontinued 
MLD & CG after 8-
24 mo 
9 6  - 43 months 
[6-120] 
C: 7/9 had reduction 
L: 5/6 had flow 
improvement 
No donor site 
morbidity  
35 Lymphvessels 
set in upper 
arm/supraclavi
cular region 
CG for 6 mo 127 31 - - V: 22% average reduction DVT (n=1), 
donor site 
edema (n=1) 
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36 Lymphvessels
set in upper 
arm/supraclavi
cular region 
CG for 6 mo 12 96  - - V: Reduction 22-31% 
L: 11/12 significant flow 
improvement (p<0.01) 
- 
 
37 MLVI CT for first 6 mo 9 
 
17 
[15-22] 
- 7.3 years 
[1-13] 
C: 77.8% had >50% 
reduction 
- 
38 LVA CT & CG 
continued 
indefinitely 
20 12 Campisi classification: 
stage II (n=10) & III 
(n=10) 
4.8 years 
[1-17] 
V: 65% had reduction, 
average 35%  
S: 80% long term 
improvement 
NR 
39 LVA  CG continued 
indefinitely 
10 12 Campisi classification: 
stage III (n=10) 
5.3 years 
[3-14] 
V: average reduction of 
2% 
S: 50% improvement after 
6 mo 
L: no improvement 
- 
40 MLVI  CG continued 
indefinitely 
18 24  
[12-72] 
- 7.1 years 
[1-23] 
C: distal arm average 
reduction 54% [0-100%], 
proximal arm average 
reduction 45% [7.1-76.5%]  
S: 100% improvement 
NR 
Time of follow-up and duration of breast cancer related lymphedema presented as mean and range.   
Abbreviations: IFP; inguinal fat pad, V, results measured by arm volume; C, results measured by arm circumference; L, results measured by 
lymphoscintigraphy; S, results measured by symptom assessment; CG, compression garments; CT, compression therapy; Pts, patients; MLVI, 
microsurgical lymphaticovenous implantation; LVA, lymphaticovenous anastomoses, NR; none reported, Mo; months, WLSE; wide local scar excision 
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Even though we were limited to level IV evidence, a preference can be given to 
the inguinal lymph node transfer based on the reviewed literature. Not only was 
this the only technique that made the discontinuation of post-operative 
conservative therapy possible, it was also the technique described in better 
methodological quality studies compared to that of the other techniques. 
Furthermore, because this surgical procedure can be combined with autologous 
breast reconstruction it might be easier to incorporate it into current breast 
cancer management programs.     
 
Conclusion 
 
An overview is presented of the current evidence base for the effectiveness of 
lymphatic microsurgery for the treatment of BCRL. We have identified important 
methodological shortcomings of the available literature. Evidence acquired 
through comparative prospective studies with uniform patient selection is 
lacking. The consistent positive findings with regard to limb volume/ 
circumference reduction and limited to no complications reported after 
microlymphatic surgery are, however, reasons to further explore these 
techniques in methodologically superior studies, perhaps answering the 
question as to when is the most appropriate time in the disease process for 
lymphatic surgery. We believe that the true contribution of micro lymphatic 
surgery for the treatment of BCRL will only be elucidated through protocolized 
treatment initiation by experienced micro surgeons. In our institution we are 
currently in the process of setting up a prospective study: an integrated care 
program in which breast cancer patients are prospectively screened for 
lymphedema and are structurally treated with conservative therapy followed by 
lymph node transplantation or derivative surgery in conservative treatment-
resistant cases. 
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Abstract 
 
Introduction: Primary aim is to give an overview of changes in axillary staging 
and treatment of breast cancer patients. Secondly, we aim to identify patients 
with a high arm/shoulder morbidity risk, and describe a strategy to improve 
early detection and treatment. 
 
Methods: Recent and initiated studies on axillary staging and treatment were 
evaluated and clustered for clinically node negative and clinically node positive 
breast cancer patients, together with studies on pathology, detection and 
(surgical) prevention and treatment of lymphedema. 
 
Results: For clinically node negative patients, the indication for axillary lymph 
node dissection in sentinel node positive patients is fading. On the contrary, 
clinically node positive patients are routinely subjected to an axillary lymph 
node dissection, in combination with other therapies associated with an 
increased lymphedema risk, such as mastectomy, adjuvant radiation- and 
(taxane-based) chemotherapy. Techniques for prevention, early detection and 
(surgical) treatment of lymphedema are being developed. 
 
Conclusion: Axillary staging and treatment in breast cancer patients with a 
clinically node negative status will become less invasive, thereby reducing the 
incidence of morbidity. Nevertheless, in patients with a clinically node positive 
status, aggressive treatment will still be required for oncologic control. For these 
patients, a surveillance program should be implemented in order to apply 
(curative) surgical treatment for lymphedema. 
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Introduction 
Breast cancer treatment is in the process of moving towards an era of more 
conservative axillary treatment. Studies have shown that in selected patient 
populations, less extensive axillary surgery does not increase the regional 
recurrence rate, nor does it decrease overall survival.
1-3
 The main advantage of 
a conservative approach towards axillary surgery is the reduction in treatment-
related morbidity. Of all, lymphedema has the highest incidence amongst 
axillary treatment related morbidities in breast cancer and is perceived as 
disabling. Swelling of the affected arm, symptoms of heaviness, paresthesia 
and decreased range of motion contribute negatively to the quality of life.
4,5
 
Studies have revealed several patient- and treatment related risk factors for 
breast cancer related lymphedema (BCRL), with most evidence pointing 
towards the axillary lymph node dissection (ALND) as an important risk factor. 
Other risk factors include greater number of dissected lymph nodes, 
mastectomy, high body mass index, adjuvant radiation therapy, and taxane-
based chemotherapy.
4,6
        
For a long time, ALND was considered standard treatment for all breast cancer 
patients. Fifteen years ago, the sentinel lymph node biopsy (SLNB) replaced 
the ALND in patients with a clinically node negative status, resulting in 
significantly lower axillary morbidity rates, without compromising regional 
recurrence rates and overall survival.
7,8
 Completion ALND was up until shortly 
considered the standard treatment in patients with a positive sentinel lymph 
node (SLN). Currently, there is a decline in the indication for completion ALND 
in patients with SLN metastases, and the clinical relevance of the SLNB in 
certain patient groups is being debated.     
The primary aim of this paper is to give an overview of current and expected 
future changes in axillary staging and treatment, and to estimate the impact of 
these changes on the incidence of arm/shoulder morbidity, and of BCRL in 
particular. Secondly, we aim to identify the group of patients still high at risk for 
BCRL and to describe a strategy to improve early detection and treatment. 
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The changing role of axillary staging and treatment 
Clinically node negative breast cancer patients 
The standard preoperative lymph node staging consists of physical examination 
of the axilla, and according to the ESMO breast cancer guideline, combined 
with an axillary ultrasound.
9
 If negative, a patient is considered clinically node 
negative, an SLNB is performed, and until recently, followed standardly by a 
completion ALND in patients with a positive SLN. The reported BCRL rate after 
completion ALND is 20%, and 6% after SLNB-only.
4
 Several randomized trials 
have been performed with the aim to investigate whether completion ALND in 
patients with metastatic SLNs could be replaced by less invasive treatment or 
even omitted. In the AMAROS trial, clinically T1-2N0 breast cancer patients with 
SLN metastases were randomized to completion ALND or axillary and 
periclavicular radiation therapy.
3
 This trial has demonstrated that axillary and 
periclavicular radiation therapy provided a five-year regional recurrence rate of 
1.03% that is comparable to 0.54% in the completion ALND group. Most 
patients were treated with breast conserving therapy (82%) and received 
adjuvant systemic therapy (90%). At five years, the BCRL rate following axillary 
radiation therapy was significantly lower than following completion ALND based 
on clinical signs (11 vs. 23%; p<0.0001), as well as based on an arm 
circumference increase of ≥10% (6% vs. 13%; p=0.0009). The higher BCRL 
rate in the completion ALND-arm might partly be explained by the fact that 6% 
of these patients underwent axillary and periclavicular radiation therapy as well, 
compared to 2% of patients in the radiation therapy-arm that received both 
therapies.
3
 In this subgroup of patients, the BCRL rate was 58%. Further, it is 
uncertain whether the stated advantage for axillary and periclavicular radiation 
therapy will persist over time, as side effects of radiation therapy evolve over a 
more prolonged time course than surgical side effects.
10
  
In the ACOSOG Z0011 trial, clinically T1-2N0 patients with 1-2 macrometastatic 
SLNs treated with breast conserving therapy were randomized to completion 
ALND or no completion ALND.
2
 Results revealed a regional recurrence rate of 
0.9% at five years after treatment for patients in whom the completion ALND 
was omitted compared to 0.5% in the completion ALND group, while it was 
estimated that 27% of the patients had residual nodal disease.
2
 Furthermore, 
overall survival was not compromised by not performing a completion ALND in 
this patient population. However, adjuvant systemic treatment was administered 
to 96% of the patients. Side effects such as seroma, paresthesia or 
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lymphedema, were reported in 70% of patients in the completion ALND-arm, 
and in 25% after SLNB alone in the first year after randomization (p≤0.001).
11
  
The IBCSG 23-01 trial also randomized clinically T1-2N0 patients to completion 
ALND or no completion ALND, though only in case of a micrometastasis in the 
SLN.
1
 Breast conserving treatment was performed in 91% of the patients, 
mastectomy in 9% and adjuvant systemic treatment was administered to 96% 
of the patients. The ALND-specimen of patients in the control arm contained 
additional lymph node metastases in 11% of the cases, but again, the regional 
recurrence rate after omitting the completion ALND was low (1.1%) and 
comparable to the completion ALND group (0.2%).    
The AMAROS, ACOSOG Z0011 and IBCSG 23-01 trial were underpowered, as 
events occurred less common than anticipated.
1-3
 Nevertheless, these trials 
suggest that for clinically node negative breast cancer patients, a completion 
ALND is no longer indicated in case of 1-2 macrometastatic SLNs when treated 
with breast conserving therapy and adjuvant systemic treatment,
2
 and neither in 
the case of a micrometastastic SLN when treated with mastectomy and 
adjuvant systemic treatment.
1
 Furthermore, axillary- with or without 
periclavicular radiation therapy instead of a completion ALND might be 
beneficial in terms of morbidity risk for mastectomy patients with a 
macrometasis in the SLN.
3
 Thus, the incidence of BCRL in the clinically node 
negative patient group is likely to decrease in the coming years due to omitting 
completion ALND in the majority of patients with SLN metastases. The 
incidence is expected to decrease even further in the future when results of 
several ongoing randomized trials become clear. One of these trials is the 
Dutch BOOG 2013-07 trial that randomizes clinically T1-2N0 breast cancer 
patients with macrometastatic SLNs treated with mastectomy, to completion 
axillary treatment or no further axillary treatment.
12
 Several other independent 
randomized controlled trials are investigating the safety of omitting the SLNB in 
clinically T1-2N0 breast cancer patients with negative axillary ultrasound 
findings who are treated with breast conserving therapy: the Dutch BOOG 
2013-08, the Italian SOUND, and the British SNIPE trial.
13-15
 The hypothesis 
that the SLNB could be safely omitted in this patient population derives from the 
fact that residual lymph node metastases in 11-27% of patients in the ACOSOG 
Z0011 and IBCSG 23-01 trials in whom completion ALND was omitted, did not 
result in a worse regional recurrence- and overall survival rate.
1,2
 Despite the 
developments of minimizing or even no longer performing invasive staging and 
treatment of the axilla, we should remain mindful that patients with a clinically 
node negative status could still develop BCRL with the risk ranging from 6 to 
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20%.
4
 As described earlier, type of breast surgery, a high body mass index, and 
adjuvant therapy could influence this risk.
4,6
  
 
Clinically node positive breast cancer patients 
Breast cancer patients with preoperatively biopsy-proven nodal metastases or 
with palpable lymph nodes that are highly suspicious for malignancy, are 
considered clinically node positive.
16
 In most of these patients an ALND should 
be performed according to ASCO and ESMO guidelines.
9,17
 These patients are 
consequently at a high risk for developing severe BCRL, especially since a 
clinically node positive status is associated with a larger primary tumor, more 
often requiring a mastectomy, adjuvant chemotherapy and radiation 
therapy.Adjuvant chemotherapy is frequently indicated in patients with nodal 
metastases and in patients without nodal metastases but with poor prognostic 
factors based on primary tumor characteristics, such as tumor grade and 
diameter. Nowadays, chemotherapy schedules containing taxanes are standard 
of care. Several studies have shown that taxanes are associated with 
generalized edema during treatment that can persist and increase the risk of 
BCRL.
18-20
 The indication for adjuvant radiation therapy of the chest wall, axilla 
and periclavicular region is based on the risk of disease relapse and type of 
breast surgery, but in case of a pathological node negative or N1 status, there 
is no consensus amongst European and North-American guidelines. Varying 
risk factors are used in the guidelines to indicate the need for adjuvant chest 
wall irradiation in mastectomy patients, such as large tumor size, a grade 3 
tumor, angio-invasive growth and age below 40 years. Independent from the 
type of breast surgery, adjuvant periclavicular radiation therapy (combined with 
breast/chest wall) is recommended in patients with ≥4 lymph node metastases. 
A prospective study concluded that patients treated with radiation therapy of the 
breast/chest wall, axilla and periclavicular region have, after only two years of 
follow-up, a risk of BCRL ranging from 21% to 25% when combined with 
ALND.
21
 Remarkably, the one-year BCRL rate after completion ALND and 
axillary and periclavicular radiation therapy was much higher in the AMAROS 
trial, to note 59% and after five years 58%.
3
 This large difference in BCRL rate 
between these studies might partly be ascribed to different BCRL definitions 
and measurement methods. In the AMAROS trial, an increase in arm 
circumference of at least 10%, or any recorded sign of lymphedema was 
defined as BCRL,
3
 while Warren et al. only used standardized arm volume 
measurements to define BCRL as an arm volume increase of at least 10%.
21
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Furthermore, a difference in the lateral border of the axillary radiation field could 
also play a role. In the AMAROS trial, the axilla was irradiated with a broad 
anteroposterior field, and a smaller, laterally-localized, posteroanterior radiation 
field. In the study of Warren et al., it seems that periclavicular nodes were 
irradiated with a much smaller anteroposterior field, with sometimes an 
additional medially-localized posteroanterior field to treat axillary level 3. This 
corresponds with a study of Graham et al., who found that there was no 
increased risk of lymphedema if the lateral border of the supraclavicular field 
did not extend laterally from the coracoid process.
22
 BCRL due to radiation 
therapy is thought to develop by increasing fibrosis over the years, resulting in 
progressive obstruction and infiltration of lymphatic structures. The risk of BCRL 
is obviously further increased when lymph nodes and vessels are removed at 
surgery.     
So, patients with a clinically node positive status and a large tumor size who are 
subjected to ALND, combined with mastectomy and radiation therapy of the 
chest wall, axilla and periclavicular region, and adjuvant chemotherapy should 
be considered as patients with a high risk for developing BCRL. Especially the 
combination of ALND and axillary radiation therapy seems to increase the risk 
of BCRL, but no randomized data are available on this specific issue. For these 
women, it is imperative that clinicians anticipate the development of severe arm 
morbidity and treat accordingly in order to maintain an acceptable quality of life. 
Although this “high-risk” group of women might be small in numbers when 
comparing to the women who will benefit from less extensive axillary treatment, 
arm lymphedema is a chronic disease that in most cases calls for lifelong 
treatment, loss of quality of life and potentially resulting in a substantial 
economic burden.
23
  
 
Pathology and early diagnosis of BCRL 
Little is known about the exact pathophysiology of lymphedema and the time it 
takes for disease progression to take place, but what is clear is that progression 
is driven by hydrostatic and osmotic changes in the lymphatic system and 
accelerated by inflammation and infection.
24,25
 This leads to irreversible 
structural changes, such as interstitial fibrosis or atrophy of smooth muscle cells 
within the lymphatic walls, rendering the lymph vessels incapable of lymph fluid 
propulsion.
26
 Nevertheless, early diagnosis and treatment initiation has proven 
to be more effective at reducing limb-volume.
27
 The aforementioned points 
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substantiate the move from the current so-called impairment (symptom)-based 
model, in which the patient is the initiative taker, towards a surveillance-based 
model for diagnosing and treating upper-limb morbidities.
28
 For BCRL this 
entails pre-operative distribution of precautionary information and limb-volume 
assessment. Even though there are no results of randomized trials available 
yet, the efficacy of such a surveillance model has been assessed in a 
prospective population-based study.
29
 Pre- and postoperative upper-limb 
volume assessment allows the start of early lymphedema treatment, 
presumably resulting in more effective treatment and less cases of chronic 
lymphedema. Implementation of a breast cancer related arm morbidity 
surveillance program into standard care could reduce the burden and should 
find its base in appropriate clinical investigations. 
 
Surgical interventions for lymphedema prevention and 
treatment 
Axillary surgery is the biggest predictor for the development of lymphedema. In 
the hopes of limiting lymphatic damage in the upper-extremity, axillary reverse 
mapping (ARM) has been proposed as a technique to further refine axillary 
surgery.
30,31
 By mapping out the afferent lymphatic system of the upper-
extremity using blue dye, a radioisotope, or indocyanine green as a tracer agent 
in conjunction with standard SLNB/ALND procedures, the lymph nodes draining 
the breast can be selected are removed. In theory, the ARM-procedure 
facilitates preservation of the lymphatic system draining the upper-extremity, 
thus reducing the risk of BCRL. An anatomical study assessing the relationship 
between the breast and the upper-extremity lymphatic drainage, reported a 
close relationship of the two systems with shared connections in 24% of the 
cases.
32
 This phenomenon is seen in clinical studies in which crossover of 
SLNB/ALND and ARM-nodes are reported, rightfully raising doubts on the 
oncological safety of the ARM technique.
33
 Moreover, the efficacy of sparing 
ARM-nodes for reducing the incidence of BCRL has yet to be confirmed in long-
term follow-up studies.
34,35
 As previously stated, achieving oncological radicality 
with preservation of the ARM-nodes is debatable. With that in mind Boccardo et 
al. developed the Lymphatic Microsurgical Preventative Healing Approach 
(LYMPHA) to be performed in conjunction with the ARM-procedure. In cases 
where crossover of SLNB/ALND and ARM-nodes are present in the axillary 
dissection plain, lymphatic venous anastomosis are made after dissection in 
order to restore the upper-extremity lymphatic drainage system. After a 4-year 
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follow-up, the Boccardo group reported a lymphedema incidence rate of 4% 
(3/74).
36
 Although it concerns only a small study, these results are quite 
promising, when compared with the incidence of BCRL after ALND and SLNB, 
20% and 6% respectively.
4
    
For a long time, treatment of BCRL consisted of symptom control and 
maintenance with manual lymphatic drainage and compression garments. The 
Dutch breast cancer guideline suggests compression stockings for three 
months in case of a 5-10% limb-volume increase. The addition of compression 
therapy as part of complete decongestive therapy could induce significant limb-
volume reduction.
37
 When maximum limb-volume reduction is achieved, 
compression stockings should be worn to retain achieved results. These 
treatment strategies are without curative intent, which for most patients means 
lifelong treatment and a constant reminder of the breast cancer period. 
Published evidence for restoring normal lymphatic function in the damaged limb 
through microsurgery has triggered the idea that a curative approach to BCRL 
is possible. The most promising is the vascularized autologous lymph node 
transfer with or without simultaneous free flap reconstruction.
38
 Once again, if 
lymphatic surgery could indeed repair the flow of a damaged lymphatic system 
after breast cancer treatment, surgery would need to be done when lymphatic 
vessels are still viable, with the aim of eliminating the need for life-long 
conservative treatment and making BCRL a disease less prevalent. 
 
Conclusion 
In conclusion, axillary staging and treatment in breast cancer patients with a 
clinically node negative status is becoming increasingly less invasive, thereby 
reducing the incidence of lymphedema of the arm, and increasing quality of life. 
Nevertheless, in some patients with a clinically node positive status, aggressive 
treatment will still be required for optimal oncologic control. For these patients, 
a surveillance program should be implemented in order to apply surgical 
treatments that are being developed to curatively treat lymphedema at an early 
stage. 
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General discussion 
Upper-limb lymphedema is one of the most debilitating chronic morbidities that 
can develop as a result of breast cancer treatment. Yet, there is little interest for 
this treatment-related complication amongst clinicians. Thankfully, the increase 
in focus on the quality of breast cancer survivorship has stimulated research on 
this topic. It is the opinion of the authors that both the detection of breast cancer 
related lymphedema (BCRL) and its treatment warrant improvement. This belief 
formed the driving force behind the initiation of the studies described in this 
thesis. In this thesis we focus on several important aspects of BCRL, such as 
the problems associated with its diagnosis, its effect on quality of life, and the 
possible role of reconstructive (breast) surgery in the pathophysiology and 
treatment.   
Diagnosing Lymphedema 
The research presented in this thesis is based on two separate cohorts of 
breast cancer survivors and on two overviews of recent literature. The women 
in the study cohorts were not prospectively assessed pre- and post-operatively 
after breast cancer surgery for the presence of BCRL, but the post-operative 
contralateral limb volume was used as a control for diagnosing BCRL. This 
outcome was combined with patient reports of self-perceived complaints known 
to be associated with BCRL. It is our opinion that with this method the patients 
with clinically relevant BCRL were identified, which ultimately is the target group 
for treatment. We understand that the lack of consensus regarding the 
diagnosis of BCRL is an important limitation in the research base of BCRL. An 
observation made when assessing the available BCRL literature is that it seems 
as if each researcher has adopted his/her preferred mode of lymphedema 
measurement as rule of law, as there are many available methods for 
measuring lymphedema. The consequence of this is described in Chapter 2, in 
which we demonstrate varying BCRL prevalence rates in one patient cohort 
when using four different modes of measurement. With this we underline the 
necessity for a consensus on the diagnostic criteria for BCRL. Furthermore, it is 
true that lymphedema assessment provides some challenges. This is in part 
due to differences in intra-observer reliability of the measurement techniques, 
the dynamic nature of the pathophysiology of lymphedema and also due to the 
discrepancy sometimes seen between patient perception and limb volume 
measurement.  Volumetry, either being the classic water displacement method 
or the optoelectronic volumeter (Perometer), is considered the most reliable 
method for the assessment of lymphedema.
1
 The optoelectronic volumeter is 
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gaining interest as the new gold standard for lymphedema assessment; 
Deltombe et al. have shown a slightly better intra-observer reliability for the 
Perometer when comparing it to the water displacement method.
2
 Moreover, 
the usage of infrared light instead of water, results in a convenient and faster 
limb volume assessment. These points make the Perometer an attractive 
substitute for the water displacement device. However, the advantage of the 
water displacement method is that it is more cost-effective and the most applied 
method and readily available device in Dutch institutions. Also, there is 
sufficient evidence reporting comparable (high reliability) results with that of the 
Perometer.
3 - 5
 Our research group has assessed three-dimensional imaging as 
a novel approach for limb volume measurements. In this study the validity and 
reliability of the 3D camera was assessed by measuring arm volume in healthy 
volunteers and by using water volumetry as the gold standard.
6
 3D 
measurements appeared to be as reliable as water volumetry, with a high intra- 
and inter rater reliability of both 0.99.6 But, as in case with the Perometer, and 
unlike the water displacement technique, the hand is not incorporated into the 
volume measurements by 3D imaging. Not having the hand included in the 3D 
limb volume measurement does not necessarily have to be problematic, as it 
can be combined with a simple circumference measurement of the dorsum of 
the hand. 3D imaging is yet to be validated in patients with lymphedema. 
In the clinical evaluation of lymphedema the focus should not only be put on 
volume changes. Although volume is important and is the most objective 
current clinical measure, using only volume may overlook a few important 
points, such as: tissue texture changes and the symptoms that patients 
experience. Firstly, the latent stage of lymphedema preceding the increase in 
volume can go unnoticed if one only focuses on volume changes.
7
 Ideally, to 
objectively determine the stage, lymphedema assessment should also take 
place on a histological level. In Chapter 4 the possible role of the Cutometer 
device for testing and monitoring biomechanical changes in the 
lymphadematous skin was evaluated. The results of this study show a 
significantly lower elasticity of the skin in upper-limb lymphedema. In healthy 
women no difference was found in the skin elasticity of both arms. This finding 
is supported by the theory that there is an increase in volume of the 
subcutaneous tissue in BCRL that affects the skin by increasing its tension at 
rest.
15
 It is hypothesized that the proportional changes within the tissue result in 
modification of the intermolecular bridging and thickening of the collagen 
bundle.
16
 The clinical use of the Cutometer as a diagnostic or follow-up tool 
warrants further investigation in a prospective setting with a larger population. A 
tool currently being used in the assessment of the early stages of BCRL when 
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swelling predominately consists of extracellular lymph fluid
8 - 14 
is the 
bioelectrical impedance spectroscopy (BIS), as it can accurately differentiate 
extracellular fluid from tissue. Secondly, because there is poor agreement 
between patient perception and objective measures
17 – 20
, patient perceptions 
should be investigated for their relationship with the pathophysiology of BCRL. 
The discrepancy between complaints and symptoms could for example be 
explained by sensory changes in the treated limb due to neurological damage 
caused by (even limited) axillary surgery or radiation treatment.
20
 Thus, 
questions that remain to be answered are: how do we differentiate sensory 
neuropathy as a consequence of surgery/radiation from that of numbness and 
tingling experienced by patients with lymphedema? Furthermore, does the 
inflammatory process activated by tissue injury as seen in BCRL
21, 22 
also cause 
dysfunction of the sensory nerves located in the epidermis? Currently, there are 
no studies that explore the symptoms caused by sensory nerve dysfunction in 
the context of the pathophysiology of BCRL. 
 
Burden of disease  
One of the most important risk factors for the development of BCRL is the 
axillary lymph node dissection (ALND).
23 – 26
 For a long time, ALND was 
considered standard treatment for all breast cancer patients. Around 15 years 
ago, the sentinel lymph node biopsy (SLNB) replaced the ALND in patients with 
a clinically node negative status, resulting in lower axillary morbidity rates, 
without compromising regional recurrence rates and overall survival.
27 – 29
 
However, BCRL rates after SLNB are not negligible. One of the largest RCT’s 
comparing morbidity rates between SLNB and ALND reported a BCRL 
incidence rate of 7% after three years in patients having undergone SLNB.
30
 
Furthermore, a review of SLNB procedure specific BCRL incidence rates by 
Shah et al. reported a range of 3% -23%.
31
 In Chapter 3 the long-term health-
related quality of life (HRQOL) of breast cancer patients with BCRL surviving 
more than 5 years after diagnosis, was assessed using the EORTC QLQ-C30 
and QLQ-BR23 in the SLNB-era. Half of the women in this cohort underwent a 
SLNB (76/145). Of these 76 women, five were diagnosed with BCRL, which 
equals to a 6.6% rate in the SLNB patients. After adjustment for BMI and age, 
the women with BCRL scored lower on the social functioning scale when 
compared to the women without BCRL. Moreover, the presented cohort as a 
whole scored lower on a majority of the functioning scales, compared to scores 
in the general Dutch population. However, it was only the BCRL group that 
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scored significantly lower on role- and social functioning. A prospective study 
comparing the long-term HRQOL of patients undergoing SLNB alone versus 
ALND observed that women reporting arm lymphedema themselves, both in the 
presence of or without objectively measured lymphedema, scored lower on all 
HRQOL domains.
17
 Thus, clinicians should be perceptive of and receptive to 
subjective reports of symptoms which might be related to lymphedema. This is 
a further plea for investigating the relationship between patient perceptions and 
the pathophysiology of BCRL.    
In plastic surgery most surgical procedures are aimed at improving HRQOL. 
There is evidence that reconstructive breast surgery has a positive effect on the 
overall wellbeing of breast cancer survivors.
32 – 36
 However, it is of interest to 
know if this positive effect is also present in patients with BCRL after breast 
reconstruction. In a cross-sectional study in chapter 5, we reported on the 
impact of BCRL on the HRQOL of breast cancer survivors with and without 
breast reconstruction. We included women who underwent autologous 
reconstruction, an implant-based reconstruction and a combination of an 
implant and latissimus dorsi flap reconstruction in the same surgical session as 
the mastectomy, or secondarily. Irrespective of having undergone breast 
reconstruction, our data suggest that BCRL has a negative effect on the QOL of 
breast cancer patients.  Thus, it goes without saying that BCRL has a negative 
impact on the HRQOL of breast cancer survivors. However, some believe that 
BCRL will be a problem of the past as breast cancer treatment is in the process 
of moving towards an era of increasingly conservative axillary treatment. Many 
patients have already benefited from the introduction of the SLNB and many 
more patients with clinically node negative breast cancer are likely to benefit 
from developments aimed at further reducing axillary treatment. Results of 
Z0011 trial suggest that a completion ALND is no longer indicated in case of 1-
2 macrometastatic sentinel lymph nodes (SLN) when the patient is treated with 
breast conserving therapy and adjuvant systemic treatment
37
, and neither in the 
case of a micrometastastic SLN when the patient is treated with mastectomy 
and adjuvant systemic treatment.
38
 Furthermore, axillary radiotherapy with or 
without periclavicular irradiation, instead of a completion ALND was reported to 
be beneficial in terms of the morbidity risk for mastectomy patients with a 
macrometasis in the SLN.
39
 However, it is uncertain whether the stated 
advantage for axillary and periclavicular radiation therapy will persist over time, 
as side effects of radiation therapy tend to evolve over a more prolonged time 
course than surgical side effects.
40
 Furthermore, patients with a clinically 
negative axillary status are still at risk of developing BCRL, with percentages 
ranging from 6 to 20%.
26
 The type of breast surgery, a high body mass index, 
                                                                                                              Chapter 9  
 132 
and use of radiotherapy and adjuvant systemic therapy can influence this 
risk.
26,41 A further specific subgroup which will remain at a significant risk of 
developing BCRL are the patients with clinically positive axillary lymph nodes. 
These patients usually present with large tumors, more often requiring a 
mastectomy, adjuvant hormonal treatment and/or chemotherapy
42 – 44 
and 
radiation therapy
45 – 47 
of the chest wall, axilla and periclavicular region. 
Especially the combination of ALND and axillary radiation therapy is known to 
increase the risk of BCRL.
46
 For these women, it is imperative that clinicians 
anticipate the development of severe arm morbidity and treat accordingly in 
order to maintain an acceptable quality of life. Thus, we must move away from 
the current so-called impairment (symptom)-based model, in which the patient 
is the initiative taker, towards a surveillance-based model for diagnosing and 
treating BCRL.
48
 This should entail pre-operative distribution of precautionary 
information and pre- and postoperative limb-volume and symptom 
assessment.
49 – 52
 The Implementation of a BCRL surveillance program into 
standard care could reduce the burden and should find its base in appropriate 
clinical investigations.  
 
Reconstructive surgery and lymphedema 
Reconstructive breast surgery is now clearly established in the arsenal of 
breast cancer management. Currently, autologous and implant based 
reconstructions are widely performed either in the same (oncologic) surgical 
session or secondarily. The wide application of reconstructive breast surgery 
has raised the question whether these procedures might have an effect in the 
development of BCRL. Current literature provides some evidence for a 
protective effect of breast reconstruction on the development of BCRL.
53 – 56
  
Our findings in Chapter 5 are in line with the current body of evidence; after 
multivariable analysis breast reconstruction was associated with a lower risk of 
having BCRL. Although, there are also studies that have reported no effect of 
reconstructive breast surgery on the incidence of BCRL.
57, 58
 Moreover, it is 
most unlikely that a randomized study will ever be performed with the aim to 
determine the effect of reconstructive breast surgery on the risk of developing 
BCRL.   
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Studies on reconstructive surgery in the context of a potential curative 
treatment option for BCRL is of interest, especially for patients who are not 
responsive to standard conservative therapy. A variety of techniques is 
described in the literature, such as derivative microsurgery in the form of 
lymphatic venular anastomoses
59 – 64 
and composite tissue transfers containing 
vascular structures and lymph nodes
65 – 70 
with varying outcomes on limb 
volume/circumference. Evidence acquired through comparative prospective 
studies with uniform patient selection is lacking. The consistent positive findings 
with regard to limb volume/ circumference reduction and limited to no 
complications reported after microlymphatic surgery are, however, reasons to 
further explore these techniques in methodologically superior studies, perhaps 
answering the question as to when is the most appropriate time in the disease 
process for lymphatic surgery. We believe that the true contribution of micro 
lymphatic surgery for the treatment of BCRL will only be elucidated through 
protocolized treatment by experienced micro surgeons.     
   
Concluding Remarks 
In this thesis we focused on lymphedema of the arm. However, experience 
gained through conducting the studies presented in this thesis has taught us 
that swelling of the trunk, breast and axilla is also considered problematic by 
those who experience it. Means of objectively measuring and monitoring 
lymphedema in these anatomical locations is technically challenging. Hopefully 
in the future, as our knowledge grows on the exact etiology and 
pathophysiology of BCRL we will be able to provide a solution for this problem. 
Perhaps the Cutometer device will find its place, after further confirmation of the 
before described results (chapter 4) in larger clinical studies, in the diagnosis of 
lymphedema of the trunk, breast and axilla.     
With regards to the management and treatment of BCRL, a structured 
approach is lacking in the national breast cancer standard of care. In most 
hospitals patients have to take the initiative themselves to seek help of a lymph 
therapist, as the treating physician often pays little attention to post-breast 
cancer treatment arm morbidities. Saying this, an integrative BCRL surveillance 
program that combines pre- and post-operative limb measurements and patient 
education on lymphedema symptoms should be implemented in standard 
breast cancer care to assist in the early identification
49 - 52 
and treatment of 
lymphedema, especially for high-risk patients. Pre-operative limb 
measurements are especially important to allow the identification of early 
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symptoms and of small post-operative changes in limb volume.
71,72
 
Furthermore, the effectivity of lymphatic microsurgery to prevent or treat BCRL 
warrants further investigation in a randomized controlled trial (RCT) comparing 
it to the current gold standard of conservative therapy. With this, we will also be 
able to retrospectively formulate clinical criteria to select patients who will 
benefit mostly from new treatment strategies, including lymphatic microsurgery.  
Implementing a multidisciplinary BCRL screening program into standard of care 
and setting up a RCT are costly and not possible without the help of external 
funding. Unfortunately, the opinion that BCRL is and will remain a relevant 
problem amongst breast cancer survivors is not shared amongst the majority of 
those in charge of distributing national grant funding for research. It is the goal 
of the authors to further pursue research on the topic of BCRL and ultimately 
obtain enough evidence to enthuse these non-believers.   
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Summary 
In chapter 1, an introduction on breast cancer related lymphedema (BCRL) is 
provided as well as the outline of the thesis. Focus is placed on certain 
important aspects of BCRL, such as issues associated with its diagnosis, its 
effect on the quality of life, and the possible role reconstructive (breast) surgery 
plays in its treatment and pathophysiology. The aim of this thesis was to gain 
better insight on the above-mentioned aspects in order to substantiate the need 
for improvement of lymphedema management amongst breast cancer 
survivors. 
Chapter 2 describes the long-term prevalence of BCRL using four different 
commonly used measuring methods in a cohort of breast cancer survivors five 
years after oncological surgery. The prevalence varied significantly depending 
on the method used for lymphedema assessment. This data underlines the 
necessity for consensus on the diagnostic criteria for BCRL. 
In chapter 3 data are presented that show that the health related quality of life 
(HRQOL) of long-term breast cancer survivors with BCRL is significantly lower 
compared to breast cancer survivors without BCRL and also significantly lower 
compared to normative data representing the Dutch speaking population in the 
Netherlands within the same age category. The women in the study cohort 
were all treated in the sentinel lymph node biopsy (SLNB) era. These results 
demonstrate the clinical relevance of BCRL as a morbidity of the upper-limb, 
despite of the less invasive axillary surgery performed in the SLNB-era.   
Ultra-structural research has given insight on the progressive nature of BCRL: 
tissue injury induces the accumulation of inflammatory cells, which ultimately 
leads to fibrosis and degeneration of smooth muscle cells in the 
lymphedematous tissue. The above-described pathogenesis process implicates 
a role of biomechanical skin changes within the development of BCRL. In 
chapter 4 the biomechanical skin changes of patients with BCRL are presented 
using a Cutometer® for assessing skin-elasticity and visco-elasticity, and the 
Corneometer® for the assessment of skin-hydration. Data of this study give 
evidence of a reduced elasticity of the skin of the affected limb in BCRL, 
suggesting the use of the Cutometer® device in the diagnostic evaluation of 
BCRL in which a continued decrement in the skin elasticity may be an 
indication of further progression of lymphedema.   
Breast reconstruction is an important component of rehabilitation after ablative 
breast surgery. These procedures do not only provide good aesthetic results, 
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but have also been demonstrated beneficial with regards to quality of life and 
body image
 
without interfering with cancer management. The wide application 
of reconstructive breast surgery has raised the question whether it should be 
considered as a risk factor or protective factor for the development of. Chapter 
5 investigated whether women who underwent breast reconstruction, as part of 
their breast cancer treatment, were less likely to develop BCRL.130 women 
who underwent unilateral mastectomy and axillary lymph node dissection 
(ALND) with or without immediate or delayed breast reconstruction between 
January 2006 and December 2010 were included in this study. After 
multivariable adjustment breast reconstruction was associated with a 
significantly lower BCRL risk, this being of interest for the surgical decision 
making process. 
In chapter 6 data are presented that show that the HRQOL of breast cancer 
survivors who have undergone breast reconstruction and have BCRL is 
significantly impaired, negating the positive effects reconstructive breast 
surgery might have on the HRQOL.  
Chapter 7 presents a systematic review that was undertaken to give an 
overview on currently available literature on the effectiveness of lymphatic 
microsurgery for the treatment of BCRL. In this review it was concluded that 
composite tissue transfer and derivative microlymphatic surgery may be a 
promising treatment option that provides limb volume/circumference reduction. 
This systematic review identified the important methodological shortcomings of 
the available literature. 
In chapter 8 an overview of the changes in axillary staging and its implications 
on the development of arm morbidity for the future is given. It was concluded 
that clinically node negative breast cancer patients would have a reduced risk 
due to less invasive axillary staging and treatment. Nevertheless, in patients 
with a clinically node positive status, aggressive treatment will still be required 
for oncologic control. These patients should be considered at high risk for 
developing BCRL.       
   
Finally, chapter 9 provides the general discussion with conclusions following 
from this thesis. 
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Samenvatting 
In hoofdstuk 1 wordt de opzet van het proefschrift beschreven en een 
introductie over “breast cancer related lymphedema (BCRL)”, oftewel 
lymfoedeem van de arm na behandeling van borstkanker, gegeven. Enkele 
belangrijke aspecten van de pathofysiologie en de behandeling van BCRL 
worden besproken, zoals problemen omtrent de diagnose, het effect op de 
kwaliteit van leven en de mogelijke rol van reconstructieve (borst-)chirurgie. Het 
doel van dit proefschrift was om een beter inzicht te verkrijgen in 
bovengenoemde aspecten en zodoende een verbetering van de zorg van 
borstkanker patiënten te waarborgen. 
 
In hoofdstuk 2 wordt de prevalentie van BCRL, vijf jaar na de behandeling 
voor borstkanker,  beschreven. In een cohort van 145 borstkankerpatiënten, 
werd de aanwezigheid van lymfoedeem gemeten met behulp van vier 
verschillende meetmethodes: volumetrie, omtrek meting, som van arm omtrek 
metingen en subjectieve klachten patroon.  De prevalentie van BCRL varieerde 
significant, afhankelijk van de methode die werd gebruikt om het lymfoedeem te 
bepalen. De gepresenteerde data benadrukken het gebrek en de behoefte aan 
een consensus omtrent diagnostische criteria voor BCRL. 
 
In hoofdstuk 3 wordt aangetoond dat de kwaliteit van leven, oftewel de quality 
of life (QOL) van borstkanker patiënten mét BCRL significant lager is dan die 
van overlevenden zónder BCRL en tevens significant lager is dan de QOL van 
vrouwen in de algemene Nederlandse populatie in dezelfde leeftijdscategorie. 
De vrouwen in het studiecohort zijn allemaal in het  sentinel lymfklier biopsie 
(SNB) tijdperk behandeld en hebben dientengevolge minder uitgebreide 
okselchirurgie ondergaan. Ondanks de beperkte okselchirurgie, bevestigen 
deze resultaten dat, de morbiditeit van BCRL in het SNB tijdperk substantieel 
is. 
 
De ontwikkeling van lymfoedeem en de progressieve aard van de aandoening 
wordt gekenmerkt door een aantal opeenvolgende pathofysiologische 
processen. Het proces wordt geïnitieerd doordat weefselschade activatie van 
inflammatoire cellen veroorzaakt, wat uiteindelijk fibrosering en vervolgens 
degeneratie van gladde spiercellen en oedemateuze huid veroorzaakt. Het 
hierboven beschreven proces impliceert het optreden van biomechanische 
huidveranderingen in de pathogenese van BCRL. In hoofdstuk 4 worden deze 
biomechanische huidveranderingen van patiënten met BCRL gepresenteerd 
met behulp van de Cutometer® voor bepaling van huidelasticiteit en visco-
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elasticiteit en de Corneometer® voor bepaling van de hydratie van de huid. 
Data van deze studie hebben aangetoond dat er een significant verminderde 
huidelasticiteit aanwezig is in de aangedane arm bij patiënten met BCRL. Dit 
impliceert het gebruik van de Cutometer® als een diagnosticum bij de evaluatie 
van BCRL, waarbij een progressieve vermindering van de huidelasticiteit 
mogelijk duidt op het ontstaan of progressie van het lymfoedeem. 
 
Tijdens of na de behandeling van borstkanker kiezen steeds meer vrouwen 
voor een borstreconstructie, waardoor de reconstructieve chirurgie een 
belangrijk onderdeel van de borstkankerbehandeling is geworden. Deze 
ingrepen zorgen niet alleen voor een verbeterde esthetiek, maar blijken ook 
een gunstig effect te hebben op de QOL en het lichaamsbeeld van deze 
patiënten, zonder hierbij te interfereren met de oncologische behandeling. De 
brede toepassing van reconstructieve borstchirurgie heeft geleid tot de vraag of 
er een associatie is tussen borstreconstructie en de ontwikkeling van BCRL. In 
hoofdstuk 5 is de invloed van borstreconstructie als onderdeel van 
borstkankerbehandeling op het ontwikkelen van BCRL onderzocht. 
Honderddertig vrouwen die een unilaterale mastectomie met een 
okselklierdissectie (OKD) hebben ondergaan, met of zonder reconstructieve 
borstchirurgie, tussen januari 2006 en december 2010 werden geïncludeerd in 
deze studie. Multivariate analyse toonde een protectieve associatie tussen 
borstreconstructie en BCRL. Deze interessante bevinding is van belang voor de 
chirurgische besluitvorming en verdient verder onderzoek. 
 
In hoofdstuk 6 wordt aangetoond dat de QOL van borstkankeroverlevenden 
die reconstructieve borstchirurgie hebben ondergaan en daarbij BCRL hebben 
ontwikkeld significant verminderd is ten opzicht van borstkankeroverlevenden 
zonder BCRL na reconstructieve borstchirurgie. Deze data impliceren dat 
BCRL het mogelijke positieve effect van borstreconstructie op de QOL teniet 
doet. 
 
Hoofdstuk 7 is een systematische review welke de huidige literatuur omtrent 
de effectiviteit van lymfatische microchirurgie als behandeling voor BCRL 
behelst. Deze review concludeert dat gemengde weefseltransplantaties, welke 
dus onder andere lymfeklieren bevatten, alsook lymfe-veneuze 
anastomoseringen mogelijke behandelingsopties zijn die voor volume-
/omtrekreductie zorgen van ledematen aangedaan door BCRL. Tevens 
identificeert deze review de belangrijke tekortkomingen van de huidige literatuur 
en dientengevolge de behoefte aan research op dit gebied. 
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In hoofdstuk 8 wordt een overzicht gegeven van de huidige veranderingen die 
plaatsvinden in de borstkankerbehandeling met betrekking tot de oksel. Er is 
momenteel een trend naar minder invasieve okselchirurgie ter stadiering en 
behandeling van borstkanker patiënten. Diverse studies naar de oncologische 
veiligheid  en de verwachte gevolgen van minder invasieve okselchirurgie op de 
ontwikkeling van BCRL zijn opgezet en de resultaten zullen over enkele jaren 
bekend zijn .  In hoofdstuk 8 wordt geconcludeerd dat het risico op BCRL zal 
afnemen  bij  borstkankerpatiënten die klinisch geen axillaire metastasen 
hebben. Toch zullen vrouwen met positieve axillaire lymfeklieren een 
agressieve behandeling moeten ondergaan met het oog op behoud van 
oncologische controle. Deze patiëntengroep moet beschouwd worden als een 
hoog risicogroep op het ontwikkelen van BCRL. 
 
Hoofdstuk 9, tenslotte, bevat de algemene discussie met de uit deze thesis 
voortvloeiende conclusies.  
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Introduction 
 
Approximately one in eight women in the Netherlands will develop breast 
cancer during her lifetime. Fortunately, due to the implementation of population 
based screening programs, advancements in treatment options and increased 
awareness, a large proportion of these women will go on to survive the initial 
treatment phase. The fact that more women are successfully being treated for 
breast cancer has caused a shift of attention towards the period after active 
cancer treatment, also known as the period of survivorship. Survivorship refers 
to the end of active cancer therapy, a period in which late effects of cancer 
treatment are prevalent. In saying this, the management of the late effects of 
breast cancer treatment is imperative for maintaining an acceptable long-term 
quality of life. In the scope of upper-arm morbidities as part of the late effects of 
breast cancer treatment, lymphedema has the highest incidence and is 
perceived as disabling. Swelling of the affected arm, symptoms of heaviness, 
paresthesia and decreased range of motion contribute negatively to the quality 
of life. Between 6% - 43% of breast cancer survivors develop breast cancer 
related lymphedema (BCRL). Studies have revealed several patient- and 
treatment related risk factors for BCRL, with most evidence pointing towards the 
axillary lymph node dissection (ALND) as an important risk factor. 
In this chapter the focus is put on the economic and societal benefits of the 
knowledge acquired through the studies gathered in this thesis.  
 
Relevance of scientific results 
 
This thesis addressed several important aspects of BCRL, such as the 
problems associated with its diagnosis, its effect on quality of life, and the 
possible role of reconstructive (breast) surgery in the pathophysiology and 
treatment.  
Most importantly, we were able to conclude that BCRL is and will remain a 
relevant problem amongst breast cancer survivors. Currently, axillary staging 
and treatment in breast cancer patients with a clinically node negative status is 
becoming increasingly less invasive, thereby reducing the incidence of 
lymphedema of the arm. Nevertheless, in patients with a clinically node positive 
status, aggressive treatment will still be required for optimal oncologic control. 
Although this “high-risk” group of women might be small in numbers when 
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comparing to the women who will benefit from less extensive axillary treatment, 
BCRL is a chronic disease that in most cases calls for life long treatment, 
decrease in quality of life and potentially resulting in a economic burden. 
Therefore, we advice implementing a BCRL surveillance program into standard 
breast cancer care in order to facilitate early lymphedema treatment.  
With regards to the treatment of BCRL, a structured approach is lacking in the 
national breast cancer standard of care. In most hospitals patients have to take 
the initiative themselves to seek help of a lymph therapist, as the treating 
physician often pays little attention to post-breast cancer treatment arm 
morbidities. Saying this, an integrative BCRL surveillance program that 
combines pre- and post operative limb measurements and patient education on 
lymphedema symptoms should be implemented in standard breast cancer care 
to assist in the early identification
 
and treatment of lymphedema, especially for 
high-risk patients. Pre-operative limb measurements are especially important to 
allow the identification of early symptoms and of small post-operative changes 
in limb volume. Furthermore, the effectivity of lymphatic microsurgery to prevent 
or treat BCRL warrants further investigation in a randomized controlled trial 
(RCT) comparing it to the current gold standard of conservative therapy. With 
this, we will also be able to retrospectively formulate clinical criteria to select 
patients who will benefit mostly from new treatment strategies, including 
lymphatic microsurgery. 
 
Target population 
 
The results of this thesis are relevant for investigators in the medical field with 
special interest in breast cancer, morbidities related to breast cancer, 
lymphedema and quality of life. In addition, this thesis is of interest to (surgical) 
oncologists, plastic surgeons, lymphedema therapists, dedicated nurses and 
lymphedema-patient platforms.  
 
Knowledge utilization and innovation 
As previously mentioned, a multidisciplinary BCRL screening program should 
be implemented in breast cancer standard of care. This will especially be 
important for “high-risk” patients. Through this approach of secondary 
prevention of BCRL we will not only be able to treat lymphedema more 
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effectively but also learn more about its pathophysiology. The idea of moving 
away from the current so-called impairment (symptom)-based model, in which 
the patient is the initiative taker, towards a surveillance-based model is an 
innovative concept in Dutch breast cancer care. In the US a few hospitals have 
already adopted this approach as standard of care with evidence of being 
potentially cost saving compared to the traditional treatment of BCRL.  
The place of lymphatic microsurgery in the treatment of BCRL is yet to be 
established in comparative prospective studies with a uniform patient group. 
This is ultimately one of the most important goals of our research group. 
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